Protocol Number:   ADCT -402-101 
 
Official Title:      Phase [ADDRESS_252018] -402 in Patients with  
Relapsed or Refractory B -cell Lineage Non Hodgkin Lymphoma (B -NHL)   
 
Study ID: [REMOVED] 
 
Document Date:  [ADDRESS_252019] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 1CLINICAL  STUDY  PROTOCOL
IND:[ADDRESS_252020]  
Number :[ADDRESS_252021] -402 in Patients with 
Relapsed or Refractory B -cell Lineage Non Hodgki n Lymphoma (B -NHL)
PROTOCOL  NO.:  ADCT -402-1 01
Sponsor: ADC Therapeutics SA
Sponsor  Contact:
[CONTACT_25290]:
Date of Original Protocol: 21 Septem ber 2015
Protocol Amendment 1 : 8 December 2015
Protocol Amendment 
2: 8March 2016
Protocol Amendment 3:
Protocol Amendment 4:
Protocol Amendment 5:
Protocol Amendment 6:
Protocol Amendment 7:[ADDRESS_252022] -402-101 Protocol Amendment 7
Date of Protocol: [ADDRESS_252023] read and understood all sections of the protocol entitled “A Phase [ADDRESS_252024] -
402 in Patients with Relapsed or Refractory  B-cell L ineage Non Hodgkin Ly mphoma (B -NHL)” 
and the accompan ying Investigator Brochure.
I agree to supervise all aspects of the protocol and to conduct the clinical investigation in 
accordance with the Protocol , dated 16October 2017 , the current version of International 
Council for Harmonisation (I CH) harmonised tripartite guideline E6: Good Clinical Practice and 
all applicable governmental regulations. I will not make changes to the p rotocol before 
consulting with ADC Therapeutics or implement protocol changes without independent ethics 
committee approval except to eliminate an immediate risk to patient s. I agree to administer study  
treatment only  to patients under m y personal supervision or the supervision of a sub -Investigator.
I will not supply  the investigational drug to any  person not authori zed to receive it. 
Confidentiality  will be protected. Patient identity  will not be disclosed to third parties or appear 
in any  study  reports or publications.
I will not disclose information regarding this clinical investigation or publish results of the 
investigation without authori zation from ADC Therapeutics SA.
Signature [CONTACT_789] [INVESTIGATOR_210893] I nvestigator
ADC The rapeutics ADCT -[ADDRESS_252025] -402-101 Protocol Amendment 7
Date of Protocol: [ADDRESS_252026] CD19 ..........25
2 Study Objectives ................................................................................................................... 26
2.1 Primary  Objectives .......................................................................................................26
2.2 Secondary  Objectives ...................................................................................................26
3 Investigational Plan and Patient Selection ........................................................................... 27
3.1 Study Design ................................................................................................................27
3.2 Dose Escalation ............................................................................................................28
3.3 Selection of Study Population ......................................................................................30
3.3.1 Inclusion Criteria
............................................................................................30
3.3.2 Exclusion Criteria ...........................................................................................32
4 Study Procedures ................................ ................................ ................................ .................. 34
4.1 Procedures b y Stud y Da y.............................................................................................34
4.1.1 Screening Period (Day  –28 to –1) ..................................................................34
4.1.2 Day 1 of Each C ycle................................ ................................ ....................... 35
4.1.3 Day 2 (C ycles 1 and 2) ................................ ................................ ................... 37
4.1.4 Day 3 (C ycles 1 and 2) ................................ ................................ ................... 37
4.1.5 Day 5 (C ycles 1 and 2) ................................ ................................ ................... 37
4.1.6 Day 8 (± 2 day s) of Each Cy cle................................ ................................ ......37
4.1.7 Day 15 (± 2 day s) of Cy cles 1 and 2 ................................ .............................. 38
4.1.8 Day 28 (± 3 day s)................................ ................................ ........................... [ADDRESS_252027] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 54.1.9 End of T reatment Visit................................ ................................ .................... 39
4.1.10 12- week Follow -up V isit................................ ................................ ................ 39
4.1.11 Long -term Follow -up......................................................................................40
4.2 Withdrawal of Patients from the Study ........................................................................40
4.2.1 Reasons for W ithdrawal/Discontinuation .......................................................[ADDRESS_252028] ................................................................................44
5.6 Management of Clinical Supplies ................................................................................45
5.6.1 Study Drug Packaging and Storage ................................................................45
5.6.2 Study Drug Preparation and Administration ...................................................45
5.6.3 Study Drug Accountability .............................................................................45
5.7 Overdose Management ................................................................................................45
5.8 Treatment Compliance .................................................................................................45
5.9 Concomitant Treatment ................................................................................................45
5.9.1 Prohibited During Stud y
.................................................................................46
5.9.2
Permitted Du ring Stud y ..................................................................................46
6 Study Assessments and Procedures
...................................................................................... 48
6.1 Efficacy  Assessments
...................................................................................................48
6.2 Pharmacokinetic and Pharmacod ynamic Assessments ................................ ................ 48
6.2.1 Pharmacokinetic Assessments ................................ ................................ ........ 49
6.2.2 Pharmacod ynami c and Other Assessments ....................................................49
6.3 Safety  and Tolerability  Assessments
............................................................................49
6.3.1 Definition of Dose -Limiting T oxicities ..........................................................50
[IP_ADDRESS] Safety  Oversight by  [CONTACT_210910] .....50
6.3.2 Adverse Events ................................ ................................ ............................... 51
[IP_ADDRESS] Definitions of Adverse Events ......................................................51
[IP_ADDRESS] Eliciting and Documenting Adverse Events .................................51
[IP_ADDRESS] Reporti ng Adverse Events ............................................................[ADDRESS_252029] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page [IP_ADDRESS] Assessment of Severit y
................................ ................................ .52
[IP_ADDRESS] Assessment of Causality ...............................................................53
[IP_ADDRESS] Follow -Up of Patients Reporting Adverse Events ........................53
6.3.3 Pregnancy .......................................................................................................53
6.3.4 Clinical L aboratory Analy ses.........................................................................54
[IP_ADDRESS] Hematology ...................................................................................54
[IP_ADDRESS] Biochemistry .................................................................................54
[IP_ADDRESS] Urinaly sis......................................................................................54
[IP_ADDRESS] Additional Renal Function Studies ...............................................54
6.3.5 Electrocardiograms .........................................................................................54
6.3.6 Physical Examination .....................................................................................55
6.3.7 Vital Sign Measurements ................................................................................55
6.3.8 Weight.............................................................................................................55
6.3.9 Eastern Cooperative Oncology  Group Performance Status ............................55
6.4 Sample Handling, Storage and Shipment ....................................................................55
7 Statistical and Anal ytical Plan .............................................................................................. 58
7.1 Safety  Endpoints ..........................................................................................................58
7.2 Primary  Endpoints .......................................................................................................58
7.2.1 Primary  Endpoints ..........................................................................................58
7.2.2 Secondary  Endpoints ......................................................................................58
7.3 Sample Size Calculations .............................................................................................59
7.4 Analy sis Sets ................................................................................................................59
7.5 Descr iption of Subgroups to be Anal yzed...................................................................59
7.6 Statistical Analy sis Methodology ................................................................................60
7.6.1 Safety  Analyses...............................................................................................60
[IP_ADDRESS] Analy ses of Adverse Events .........................................................60
[IP_ADDRESS] Clinical L aboratory  Results ..........................................................60
[IP_ADDRESS] Addi tional Safety  Assessments .....................................................60
7.6.2 Efficacy  Analysis................................ ................................ ............................ 61
[IP_ADDRESS] Overall Response Rate ..................................................................61
[IP_ADDRESS] Duration of Response ...................................................................61
[IP_ADDRESS] Overall Survival ............................................................................61
[IP_ADDRESS] Progression
-Free Survival ............................................................[ADDRESS_252030] -402-101 Protocol Amendment 7
Date of Protocol: [ADDRESS_252031] of the Study .......................................................................................64
8.3
Patient I nformation and Consent ................................ ................................ ................. 64
9 Investigator ’s Obligations..................................................................................................... [ADDRESS_252032] ..............................................................................................................66
9.6 Adherence to Protocol ..................................................................................................66
9.7 Investigator ’s Final Report ..........................................................................................[ADDRESS_252033] ....................................................................................................................... 70
12 Appendices ........................................................................................................................... 73
12.1 Appendix: Schedule of Events .....................................................................................73
12.1.1 Schedule of Stud y Procedures ........................................................................74
12.1.2 Timings for ECG , PK, P D, and Exploratory  Assessments .............................. 78
12.2 Appendix: Response Assessment of Hodgkin and Non- Hodgkin L ymphoma (Lugano 
Classification) ..............................................................................................................79
12.3 Appendix: CTCAE I mmune Sy stem Hy persensitivity  Grades ....................................[ADDRESS_252034] -402-101 Protocol Amendment 7
Date of Protocol: [ADDRESS_252035] -402 .................................................................... 29
Table 2.
Definition of Severit y Grades for Common T erminology  Criteria for Adverse 
Events (CTCAE) ................................................................................................... 53
Table 3. Definition of Eastern Cooperative Oncology  Group (ECOG) Pe rformance Status 
Grades ................................................................................................................... [ADDRESS_252036] -
402................................ 23
Figure 2. Schematic Representation for Dose Escalation (3+3) Design ....................................... [ADDRESS_252037] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 9Protocol Synopsis
Protocol 
Number:ADCT -402-101
Title: A Phase 1, Dose -escalation Study  to Evaluate the Tolerability, Safety, 
Pharm acokinetics, and Antitumor Activity of ADCT -402 in Patients with 
Relapsed or Refractory B -cell Lineage Non Hodgkin Lymphoma 
(B-NHL)
Sponsor: ADC Therapeutics SA
Study Phase: Phase 1
Study S ites: Approximately 11sites during dose escalation (Part 1) and 12sites during 
dose expansion (Part 2)
Indication: Patients with relapsed or refractory B-cell lineage non-Hodgkin 
Lymphoma (B -NHL) who have failed, or are intolerant to, any established 
therapy ; or for whom no other treatment options are available, in t he 
opi[INVESTIGATOR_689] .
The DESC will determine which histologic sub -types will be investigated 
in Part 2 of the study based on the emerging efficacy and tolerability 
profile from part 1.
B-cell NHL defined as:
Diffuse large B -cell ly mphoma (DLBCL)
Follicular ly mphoma (FL)
Chronic ly mphocy tic leukemia (CLL)
Mantle cell lymphoma (MCL)
Marginal Zone B -cell Lymphoma (MZBCL)
Burkitt’s lymphoma (BL)
Lymphoplasmacy tic ly mphoma (Waldenstrom macroglobulinemia 
[WM]) .
Rationale: Non-Hodgkin Lymphoma is the seventh most common type of cancer in 
the U.S., and will account for an estimated 4.3% (n=71,850) of new 
cancer cases in [ADDRESS_252038] commonly a disease of older individuals 
with approximately 75% of new cases diagnosed in individuals 55 years 
of age o r older (median age at diagnosis = 66 years). Response to initial 

ADC The rapeutics ADCT -[ADDRESS_252039] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 10treatment generally exceeds 50% and the overall 5 -year survival rate in the 
U.S. is 70%. However, a significant proportion of patients will relapse. 
The poor prognosis for relapsed patients, especially those with chemo -
refractory  disease with a short interval between remission and relapse, or 
those who relapse after high -
dose therapy  and autologous stem cell 
transplant (ASCT ), highlights the need for new forms of treatment for 
NHL.
In normal human tissue, expression of cluster of differentiation 19 (CD19) 
is limited to the developmental stages of the B cell and is lost in terminally 
differentiated plasma cells. Expression of CD19 is maintained in 
hematologic B -cell malignancies, including B -NHL.
ADCT -402 is an antibody drug conjugate (ADC) composed of a 
humanized monoclonal antibody , directed against human CD19, 
conjugated to SG3199, a pyrrolobenzodiazepi[INVESTIGATOR_050] (PBD) dimer cytotoxin, 
through a protease -cleavable valine -alanine linker. The PBD dimer
cytotoxin (SG3199) attached to the linker is designated as SG3249.
The potential for ADCT -[ADDRESS_252040] -402 is not pharmacologically cross -reactive (active) in any  
standard species used for nonclinical safety assessment. In the absence of 
CD19 target engagement, it was not possible to nonclinically evaluate the 
safety  consequences associated with possible B -cell depletion. However, 
the impact and overall safety of B -cell depletion has been investigated 
clinically and nonclinically with other B -cell depleting agents and has 
been shown to be safe and well tolerated . Thesafety studies therefore
assess edthe potential off -target effects of ADCT -[ADDRESS_252041] -402 is well tolerated at doses up to 2 mg/kg. A repeat -
dose Good Laboratory  Practice (GL P) toxicology  study  in cy nomolgus 
monkey s investigated doses from 0.3 to 0.6 mg/kg with the 0.6 mg/kg 
dose identified as the highest non severe toxic dose (HNSTD). T oxicity  
in the monkey  was characterized by  [CONTACT_210911] -dependent skin 
changes (h yperpi[INVESTIGATOR_210894] / hyperkeratosis), 
reversible dose -
dependent anemia associated with some bone marrow 
hypocellularity , reversible dose -dependent nephropathy  and 
dose-dependent testicular toxicity  (atroph y with reduced 
spermatogenesis, expected to be reversible ).
Objectives: Primary Objectives
Evaluate the safety and tolerability ,and determine , as appropriate, the 
maximum tolerat ed dose (MTD) of ADCT -402 in patients with 
relapsed or refractory B -cell lineage NHL (Part 1) .

ADC The rapeutics ADCT -[ADDRESS_252042] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 11Determine the recommended dose (s)of ADCT -402 for Part 2 
(expansion).
Evaluate the safety and tolerability of ADCT -402 in Part 2 
(expansion) at the dose level (s)recommended in Part 1 .
Secondary Objectives
Evaluate the clinical activity  of ADCT -402 as measured by [CONTACT_178975] (ORR), duration of response (DOR), progression-free 
survival (PFS), and overall survival (OS).
Characterize the pharmacokinetic (PK ) profile of ADCT -402 (total 
antibody ; drug to -antibody ratio [DAR] ≥0), PBD -conjugated 
antibody  (DAR ≥1), and free warhead SG3199.
Evaluate anti-drug antibodies (ADAs) in blood before, during, and 
after treatment with ADCT -402.
 
 
 
 
 
 
 
 
 
Patient
Selection :Inclusion Criteria
1.Part 1: Male or female patients, ages [ADDRESS_252043] failed or are intolerant to established therapy, or for whom 
no other treatment options are available, in the opi[INVESTIGATOR_684].
Refractory  or relapsed B -cell NHL (per World health Organization 
[WHO ]Classification sy stem) defined as: 
Diffuse large B -cell lymphoma (DLBCL),
Follicular lymphoma (FL),
Chronic ly mphocy tic leukemia (CLL),
Mantle cell lymphoma (MCL),
Marginal Zone B -cell Lymphoma (MZBCL),

ADC The rapeutics ADCT -[ADDRESS_252044] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 12Burkitt’s lymphoma (BL),
Lymphoplasmacy tic ly mphoma (Waldenstrom macroglobulinemia 
[WM]).
Part 2: Eligible histologic sub -types to be investigated in part [ADDRESS_252045] 
no other treatment options are available, in the opi[INVESTIGATOR_684].
The DESC may  establish specific patient populations within each 
hitological subty pe to be investigated such as specific prior treatments.
2.Availability  of formalin -fixed paraffin -embedded (FFPE) tumor tissue 
block. An FFPE block from a current biopsy is preferred; however,
archival tissue taken at initial diagnosis or any prior relapse is 
acceptable. If tissue block is not available, slides from a FFPE block 
may be accepta ble for eligibility upon consultation with the Sponsor.
3.Measurable disease, as defined by [CONTACT_941] 2014 Lugano Classification.
4.Eastern Cooperative Oncology Group (ECOG) performance status
0 to 2.
5.Absolute neutrophil count (ANC) ≥1000/µL.
6.Platelet count of ≥7500 0/µL.
7.Hemoglobin ≥9.0 g/dL without transfusion within the 2 weeks prior to 
Day 1.
8.Serum /plasma creatinine ≤1.5 mg/dL . If the patient has a creatinine 
>1.5mg/dL, a measured creatinine clearance must be >60mL/min as 
calculated by [CONTACT_210912].
9.Serum /plasma alkaline phosphatase, a lanine aminotransferase (ALT), 
and aspartate aminotransferase (AST) ≤2 times the upper limit of 
normal (ULN); ≤ [ADDRESS_252046] if there is liver or bone involvement.
10.Total serum /plasma bilirubin ≤1.[ADDRESS_252047] (patie nts with known 
Gilbert’s syndrome may  have a total bilirubin up to ≤[ADDRESS_252048]).
11.Negative serum or urine beta -human chorionic gonadotropin (β-HCG)
pregnancy  test within 7 days prior to Day 1 for women of childbearing 
potential .
12.Women of childbearing poten tial* must agree to use a highly 
effective** method of contraception from the time of giving informed 
consent until at least [ADDRESS_252049] -402.
*Women of childbearing potential are defined as sexually mature 

ADC The rapeutics ADCT -[ADDRESS_252050] -402-101 Protocol Amendment 7
Date of Protocol: [ADDRESS_252051] not undergone bilateral tubal ligation, bilateral 
oophorectomy , or hy sterectomy ; or who have not been 
postmenopausal (i.e., who have not menstruated at all) for at least 1 
year.
**Highly  effective forms of birth control are methods which achieve a 
failure rate of less than 1% per year when used consistently and 
correctly . Highly effective forms of birth control include: Hormonal 
contraceptives (oral, injectable, patch, intrauterine devices), male 
partner sterilization, or total abstinence from heterose
xual intercourse, 
when this is the preferred and usual lifestyle of the patient. 
Note: The double -barrier method (e.g., synthetic condoms, diaphragm, 
or cervical cap with spermicidal foam, cream, or gel), p eriodic 
abstinence (such as calendar, symptotherm al, post -ovulation), 
withdrawal (coitus interruptus), lactational amenorrhea method, and 
spermicide -only  are not acceptable as highly effective methods of 
contraception .
Exclusion Criteria
1.Patients who, in the opi[INVESTIGATOR_689], have any option f or 
other treatment for B -cell NHL at the current state of disease.
2.Active graft -versus -host disease.
3.Autologous or allogenic transplant within the 60 days prior to the 
Screening visit.
4.Known history of immunogenicity or hypersensitivity to a CD19 
antibody.
5.Evidence of my elody splasia or my eloid leukemia by [CONTACT_5293], 
immunostains, flow cytometry, or cytogenetics on a bone marrow 
aspi[INVESTIGATOR_5179].
6.Known history of positive serum human ADA.
7.Active autoimmune disease, motor neuropathy considered of 
autoimmun e origin, and other central nervous system (CNS )
autoimmune disease. Known seropositive for human 
immunodeficiency  (HIV) virus, hepatitis B surface antigen (H BsAg), 
or antibody  to hepatitis C virus (anti -HCV) with confirmatory testing 
and requiring anti -viral therapy.
Note: Testing is not mandatory to be eligible. Testing for HCV should 
be considered if the patient is at risk fo r having undiagnosed HCV 
(e.g., history  of injection drug use).
8.History  of Steven's Johnson's syndrome or toxic epi[INVESTIGATOR_210895] s 
syndrome.
9.Pregnant or breastfeeding women.
10.Significant medical comorbidities, including uncontrolled 
hypertension (diastolic blood pressure greater than 115 mm Hg), 
unstable angina, congestive heart failure (greater than [LOCATION_001] Heart 

ADC The rapeutics ADCT -[ADDRESS_252052] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 14Association class 
II), severe uncontrolled ventricular arrhythmias, or 
electrocardiographic evidence of acute ischemia, poorly controlled 
diabetes, severe chronic pulmonary disease, coronary angioplasty, or 
myocardial infarction within 6 months prior to screening, or 
uncont rolled atrial or ventricular cardiac arrhythmias.
11.Use of any  other experimental medication(s) within 14 day s or 
5half-lives but in no case less than 14 days prior to start of study 
treatment on Cycle 1, Day 1 , except if approved by  [CONTACT_2728].
12.Steroid use eq uivalent to greater th an 20 mg of prednisone within 
4weeks (28 day s) prior to Day  1, except for the use of short course 
systemic corticosteroids ( ≤ 7 day s), with a wash-out period of 1 week 
prior to start of study treatment on Day 1.
13.Major surgery , chemotherapy , systemic therapy  (excluding steroids
hydroxy urea steroids , and any targeted small molecules or biologics ), 
or radiotherap y, within 14days or 5 half -lives (whichever is 
shorter) prior to C ycle 1, Day 1 treatment, except if approved b y the 
Sponsor .
14.Failure to recover (to Common Terminology Criteria for Adverse 
Events [CTCAE] Grade 0 or Grade 1) from acute non hematologic 
toxicity(except all grades alopecia or Grade 2 or lower neuropathy ), 
due to previous therapy, prior to Screening.
15.Congenital long QT syndrome or a corrected QTc interval ≥450 ms at 
the Screening visit (unless secondary to pacemaker or bundle branch 
block).
16.Active second primary malignancy other than non -melanoma skin 
cancers, non- metastatic prostate cancer, in situ cervical cancer, ductal 
or lobular carcinoma in situ of the breast, or other malignancy that the 
Sponsor’s medical monitor and Investigator agree and document 
should not be exclusionary. 
17.Any other significant medical illness, abnormality, or condition that 
would, in the Investigator’s judgment, make the patient inappropriate 
for study participation or put the patient at risk.

ADC The rapeutics ADCT -[ADDRESS_252053] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 15Study Design: This is a Phase 1, open -
label, dose escalation (Part 1) and expansion 
(Part 2) study of the safety and tolerability of ADCT -402, used as 
monotherapy , in patients with relapsed or refractory B -NHL. The study 
will determine the MTD, as well as evaluate the preliminary activity, PK, 
pharmacody namics (PD), and other exploratory assessments of 
ADCT -402.
In Part 1, patients will be assigned to treatment according to a 3+3 dose 
escalation design (see below) and with oversight by a Dose Escalation 
Steering Committee (DESC). 
In Part 2, (expansion), all patients will be assigned to the recommended 
dose level(s) and schedule(s) of AD CT-402 identified in Part 1.
Estimated 
Duration of 
Patient 
Participation 
and Study 
Duration:For each patient, the study will include a scre ening period (up to 28 days), 
atreatment period (until withdrawal), and a follow -up period to assess 
disease progression and survival for up to [ADDRESS_252054] dose of 
study  drug. The total study duration will be dependent on overall patient 
tolerability  to the study  drug and response to treatment. It is anticipated 
that the duration of the entire study (Part s 1 and 2) could be approximately 
3years from first patient treated to last patient completed.
Patients who discontinue treatment for any reason other than disease 
progression will continue to be followed approximately every [ADDRESS_252055] disease assessment until disease progression, or initiation of 
new anticancer treatment. After documentation of disease progression or 
start of new treatment, patients will be followed (by [CONTACT_210913]) approximately every [ADDRESS_252056] survival information.
Patients may  withdraw from the study at any time and for any reason, 
without prejudice to their future medical care, by [CONTACT_210914]. 
Efficacy 
Assessments:Disease assessments will be conducted within [ADDRESS_252057] cycle (i .e., Cycles 8, 11, 14, etc.), 
until disease progression, or more frequently, if clinically indicated. The 
same methods used a t Screening which identify sites of disease should be 
used uniformly  for all subsequent assessments. If PET -
CT is positive, 
subsequent diagnostic CT and MRI are not needed unless clinically 
indicated .PET-CT is not required if a PET -CT examination at Scree ning 
was negative.
For patients who have reduced dosing frequency and are following a 
6week schedule, disease assessments should occur approximately [ADDRESS_252058] every 12 
weeks. It is understood that t here will be a ± 6 day window for restaging 
of these patients.
The patient’s response to treatment will be determined by [CONTACT_210915] (CR), partial response (PR), stable disease (SD), or 
progressive disease (PD), based on the [ADDRESS_252059] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 16Criteria.
Pharmacokinetic
and Anti -drug
Antibody 
Assessments:The PK profile of ADCT -402 (total antibody; DAR ≥0), PBD -conjugated 
antibody  (DAR ≥1), and free warhead SG3199 will be assessed using 
measures from validated bioanaly tical methods . The PK profile will 
include determination of standard PK parameters (e.g., maximum 
concentration [C max], time to C max[Tmax]).
The following pharmacodynamic and other exploratory assessments will 
be performed at various time points in the study:
 
Level of ADAs against ADCT -402 in serum. 
 
Serum concentrations of ADCT -402 and free warhead SG3199 will 
be determined. The QTc interval will also be measured.
Safety 
Assessments:Safety  will be assessed based on the evaluation of adverse events (AEs ), 
serious AEs (SAEs), treatment discontinuations due to AEs, dose limiting 
toxicity (s)(DLTs), periodic 12 -lead electrocardiogram (ECG) recordings, 
physical examinations, vital signs measurements, ECOG performance 
status, and hematology, coagulation panel and pregnancy testing (for 
women of child -bearing potential) , biochemistry, and urinal ysis test 
results obtained at various timepoints during the study. Adverse events 
will be graded according to CTCAE Version 4.0.

ADC The rapeutics ADCT -[ADDRESS_252060] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 17Definition of 
DLTA dose-
limiting toxicity ( DLT)is defined as any  of the following events, 
except those that are clearly due to underly ing disease or extraneous 
causes.
A hematologic DLT is defined as:
Grade 3 or 4 febrile neutropenia or neutropenic infection.
Grade 4 neutropenia lasting >7 days.
Grade 4 thrombocytopenia.
Grade 3 thrombocytopenia with clinically significant bleeding, or 
Grade 3 thrombocytopenia requiring a platelet transfusion.
Grade 4 anemia.
A non-hematologic DLT is defined as:
Grade 4 tumor lysis syndrome (Grade 3 TLS will not constitute DLT 
unless it leads to irreversible end -organ damage).
Grade 3 or higher AE (including nausea, vomiting, diarrhea, and 
electroly te imbalances lasting more than 48 hours despi[INVESTIGATOR_28052] ; excluding all grades of alopecia).
Grade 3 or higher hypersensitivity reaction (regardless of 
premedication).
Grade [ADDRESS_252061], Dosage, 
and Mode of 
Administration:ADCT -402 is a sterile formulation containing PBD -conjugated humanized 
monoclonal IgG1 antibody (DAR ≥1), humanized monoclonal IgG1 
antibody  (DAR = 0), and SG3249. It is provided pre -formulated in [ADDRESS_252062] -402 per vial 
(deliverable volume 3 .2mL at 5 mg/mL).
Patients will receive a 1 -hour intravenous (IV) infusion of ADCT -402, at 
escalating doses, on Day  [ADDRESS_252063] cycle, the infusion duration may be shortened to 30 minutes 
for subsequent cycles for that patient, at the Investigator’s discretion.

ADC The rapeutics ADCT -[ADDRESS_252064] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 18Dose -
Escalation 
Design:In Part 1, patients will be assigned to treatment with ADCT-402 at 
escalating doses according to a 3+[ADDRESS_252065] -402 will be 15 µg/kg (Dose Level 1), and the highest allowed dose 
will be 300 µg/kg. 
Further dose levels and schedules evaluated incl ude the following:
120 µg/kg:  Dosing every [ADDRESS_252066] 
SD after the second cycle continue tr eatment at a reduced dose of 
60µg/kg q6weeks, beginning 6 weeks after Cycle 2 infusion.  
150 µg/kg: Dosing every [ADDRESS_252067] 
SD after the second cycle continue tr eatment at a reduced dose of 
60µg/kg q6weeks, beginning 6 weeks after Cycle 2 infusion.  
200 µg/kg: Dosing every [ADDRESS_252068] SD 6 weeks after Cycle 2 , continue treatment at a reduced dose 
of 60 µg/kg q6weeks, beginning 6 weeks after Cycle 2 infusion.
200 µg/kg: Dosing every [ADDRESS_252069] SD 
6weeks after Cy cle 1, continue treatment at a redu ced dose of 
60µg/kg every  [ADDRESS_252070] patient enrolled into the study at 15 µg/kg (Dose Level 1)must 
be observed for [ADDRESS_252071] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 19Dose -
Expansion 
Design:In Part 2, (expansion), patients will be assigned to the recommended dose 
level(s) and schedule(s) of ADCT -402 identified in Part 1 base d on 
evolving safety, efficacy and pharmacokinetic data.
The population in Part 2 expansion may be restricted to specific 
histologies based on both signals of activity and the safety observed in 
Part 1.  
Further, dose levels and schedules evaluated in Par t 2 may  include but are 
not limited to the following:
90, 120, 150, 200 µg/kg:  Dosing every 3 weeks.
120 µg/kg:  Dosing every [ADDRESS_252072] SD 
after the second cycle continue treatment at a reduced dose of 60 µg/kg 
q6weeks, 
beginning 6 weeks after Cycle 2 infusion.  
150 µg/kg: Dosing every [ADDRESS_252073] SD 
after the second cycle continue treatment at a reduced dose of 60 µg/kg 
q6weeks, beginning 6 weeks after Cycle 2 infusion.  
200 µg/kg: Dosi ng every [ADDRESS_252074] 
SD 6 weeks after Cycle 2, continue treatment at a reduced dose of 60 
µg/kg q6weeks, beginning 6 weeks after Cycle 2 infusion.
200 µg/kg: Dosing every [ADDRESS_252075] SD 6 weeks
after Cy cle 1, continue treatment at a reduced dose of 60 µg /kg every  6 
weeks beginning 6 weeks after Cycle 1 infusion.
Sample Size: This is a Phase [ADDRESS_252076] -402-101 Protocol Amendment 7
Date of Protocol: [ADDRESS_252077] aspartate aminotransferase
AUC 0-∞ area under the concentration -time curve from time zero to infinity
AUC 0-last area under the concentration -time curve from time zero to the last 
quantifiable concentration
AUC 0-τ area under the concentration -time curve from time zero to the end of the
dosing interval
BSA body  surface area
CBC complete blood count
CD cluster of dif ferentiation
CFR Code of Federal Regulations
CI confidence interval
CL clearance
Cmax maximum concentration
CNS central nervous s ystem
CR complete response
CRO contr act research organization
CT computed tomograph y
CTCAE Common Terminology  Criteria for Adverse Events
D5W 5% dextrose in water
DAR drug-to-antibody  ratio
DESC Dose Escalation Steering Committee
DLT dose-limiting toxicity
DOR duration of response
ECG electrocardiogram
ECOG Eastern Cooperative Oncology  Group
eCRF electronic case report form
EOI end of infusion
ADC The rapeutics ADCT -[ADDRESS_252078] -402-101 Protocol Amendment 7
Date of Protocol: [ADDRESS_252079] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 22Abbr eviation Definition
PT prothrombin time
PTT partial thromboplastin time
QWBA Quantitative whole -body  autoradiograph y
q6weeks Every  6 weeks
RB4v1.2 human monoclonal antibody  being studied
SAE serious adverse event
SAP statistical analy sis pla n
SCID Severel y combined immunodeficiency
SD stable disease
TEAE treatment -emergent adverse event
TLS tumor ly sis sy ndrome
λz terminal elimination phase rate constant
Tmax time to maximum concentration
T1/[ADDRESS_252080] -402-101 Protocol Amendment 7
Date of Protocol: [ADDRESS_252081]
-402 is an antibody  drug conjugate (ADC) composed of a humanized antibody  (RB4v1.2) 
directed against human cluster of differentiation 19 (CD19), attached with a cathepsin -cleavable 
linker to SG3199, a py rrolobenzodiazepi[INVESTIGATOR_050] (PBD) dimer cy totoxin. 
The PBD dimers are highly  efficient anticancer drugs that bind in the minor groove of DNA and 
form highl y cytotoxic DNA interstrand cross- links. The schematic representation of ADCT-[ADDRESS_252082] -402
Abbreviations: Ala, alanine; P ABA, para -aminobenzoic acid; PEG , polyethylene glycol; RB4v1.2, human 
monoclonal antibody being studied; V al, valine. 
The make -up of ADCT -402includes:
RB4v1.2: A humanized monoclonal antibody  specific for human CD19 of the immunoglobin 
G1 (IgG1) , kappa isot ype, generated by [CONTACT_210916]- B4 (anti -CD19) antibod y (Roguska, 1996).
SG3249:  A PBD linker that comprises the PBD dimer SG3199 and all linker components, 
including the maleimide, 8
-polyethylene gl ycol, a protease -sensitive valine -alanine linker 
and a para -aminobenzoic acid (P ABA) self -immolative group.
ADCT-[ADDRESS_252083]-402 is transported to the ly sosomes, where the protease sensitive linker is cleaved and 
free PBD dimers are released inside the target cell. The released PBD dimers bind into the minor 
groove of DNA and form highl y cytotoxic DNA interstrand cross- links (Hartley , 2011a ). The 
cross -links formed b y PBD dimers are relati vely non -
distorting of the DNA structure, making 
ADC The rapeutics ADCT -[ADDRESS_252084] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 24them hidden to repair mechanisms, allowing for a longer effective period ( Adair, 2012
)and 
effectiveness in tumor cell lines resistant to other forms of chemotherap y.
1.[ADDRESS_252085] - 402in patients with B-cell
non-Hodgkin Ly mphoma (NHL) .
1.2.[ADDRESS_252086] common ty pe of cancer in the U.S., and will account for an estimated 4.3% (n=71,850) of 
new cancer cases in [ADDRESS_252087] commonly  a disease of older individuals with approximately
75% of new cases diagnosed in individuals 55 y ears of age or older (median age at diagnosis = 
66years) ( National Cancer Institute 2015). The two most common ty pes of NHL, diffuse large 
B
-cell ly mphoma (DLBCL) and follicular l ymphoma (FL) ,together account for more than half 
of all NHL cases ( The Non -Hodgkin's Lymphoma Classification Project, 1997 ;Swerdlow, 
2008).
Combination chemotherapy  or chemo -immunotherapy , with or without radiotherap y, is the most 
common initial treatment for most ty pes of NHL ( Ansell, 2015
; Evens et al, 2015 ). Response to 
initial treatment generally exceeds 50% and the overall 5 -year survival rate in the U.S. is 70% 
(National Cancer Institute 2015). However, a significant proportion of patients will relapse. The 
current standard of care for relapsed NHL is additional chemotherap y, which can be followed b y 
allogeneic stem cell tran splantation (ASCT) . The poor prognosis for relapsed patients, especially  
those with chemo -refractory  disease with a short interval between remission and relapse, or those 
who relapse after high -dose therap y and ASCT, highlights the need for new forms of tr eatment 
for NHL ( Chao, 2013 ; Mounier and Gisselbrecht, 2011
).
1.2.2 Biology of CD19
Human CD19 is a 95 kilodalton (kDa) t ype I transmembrane gl ycoprotein belonging to the 
immunoglobulin Ig super family  (Carter and Barrington, 2004 ; Tedder, 2009 ). In normal human 
tissue, expression of CD19 is restricted to the various stages of B cell development, from earl y 
pre B stage to mature B cells ,but is lost in terminal ly differentiated plasma cells ( Haas and 
Tedder, 2005 ; Scheuermann and Racila, 1995 ). Once bound to an antibody , CD19 is rapi[INVESTIGATOR_210896] ( Gerber , 2009; Blanc, 201 1). It is not shed into the circulation to the 
extent observed with other CD antigens 0F1(Cooper , 2004 ), therefore low to no levels of soluble 
CD19 are present to compete with binding at the target tissu e. 
Expression of CD19 is maintained in B -cell malignancies , including DLBCL, Burkitt’ s 
lymphoma, and FL . Additionally , CD19 expression is maintained in B -cell tumors which have 
1Note:  A report of soluble CD19 detected in the cerebrospi[INVESTIGATOR_210897] B -
cell lymphoma was 
recently published ( Muniz, 2014).
ADC The rapeutics ADCT -[ADDRESS_252088] -402-101 Protocol Amendment 7
Date of Protocol: [ADDRESS_252089] expression of CD20 after anti
-CD20 monoclonal antibody  treatment ( Anderson, 1984, 
Scheuermann and Racila, 1995 ; Wang, 2012 ).
1.2.[ADDRESS_252090]-
402 is not pharmacologicall y cross -reactive (active) in any  standard species used for 
nonclinical safet y assessment ( Blanc, 2011) . In the absence of CD19 target engagement in the rat 
and monkey , it is not possible to evaluate the safety consequences associated with likely  B-cell 
depletion . However, the impact and overall safet y of B-cell depletion has been investigated 
clinically  and nonclinically  with other B -
cell deleting agents and been shown to be safe and well 
tolerated (Kimb y, 2005; Chen and Cohen, 2012).
Therefore, t he safet y studies performed assess the potential off -target effects of ADCT -[ADDRESS_252091] -402 on the tissues associated with ‘normal’ antibod y clearance. In rats, 
ADCT-402 is well tolerated at doses up to 2 mg/kg.  
 
 
 
As per guidance from the Food and Drug Administration (FDA), thestarting dose of ADCT-
402 
chosen for this stud y is 15µg/kg .
See the Investigator Brochure for ADCT-[ADDRESS_252092] CD19 are currentl y in clinical development with 
different manufacturers (Jabbour, 2015 ), only  one is commerciall y available in the U.S . 
Blinatumomab (Blincy to, [COMPANY_010], Thousand Oaks, CA) is a bispecific CD19 -directed CD3 T -
cell engager indicated for the treatment of Philadelphia chromosome -negative, relapsed or 
refractory  B-ALL. The antibody  binds to CD19 on B -lineage cells and to CD3 on T cells . The 
most commonly  reported adverse reactions reported with its use includ e pyrexia, headache, 
peripheral edema, febrile neutropenia, nausea, h ypokalemia, and constipation ([COMPANY_010], 2014
).

ADC The rapeutics ADCT -[ADDRESS_252093] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 262Study Objectives
2.1 Primary Objectives
Evaluate 
thesafety and tolerability ,and d etermine ,as appropriate ,the maximum tolerated 
dose (MTD) of ADCT -402in patients with relapsed or refractory  B-cell lineage NHL in 
Part1.
Determine the recommended dose(s)of ADCT -402forPart 2 ( expansion
).
Evaluate the safet y and tolerability of ADCT -402 in Part 2 (expansion) at the dose level (s)
recommended in Part 1.
2.2 Secondary Objectives
Evaluate the clinical activity  of ADCT -402 as measured b y overall response rate (ORR),
duration of response (DOR), overall survival (OS) , and progression
-free survival (PFS) .
Characterize the pharmacoki netic (PK) profile of ADCT -402 (total antibody; drug to -
antibody  ratio [DAR] ≥0), PBD- conjugated antibody  (DAR ≥1), and free warhead SG3199.
Evaluate anti -drug antibodies (ADAs) to ADCT -[ADDRESS_252094] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 273Investigational Plan andPatient Selection
3.1 Study Design
This is a 
Phase 1, open -label , dose escalation (Part 1) and expansion (Part 2) study of the safety  
and tolerabil ity of ADCT -402, used as monotherapy , in patients with relapsed or refractory  
B-cell NHL. The study will determine the MTD, as well as evaluate the preliminary activity, PK, 
pharmacod ynamics , and other exploratory  assessments of
ADCT-402.
Patients will rec eive a 1 -hour intravenous ( IV)infusion of ADCT-402, at escalating doses, 
onDay [ADDRESS_252095] cy cle, the infusion duration 
may be shortened to 30 minutes for subsequent cycles for that patient, at the Inves tigator’s 
discretion.
For each patient, the study will include a screening period (up to 28 day s), a treatment period 
(until withdrawal, Section 4.2), and a follow -up period to assess disease progression and sur vival 
for up to [ADDRESS_252096] dose of study  drug. The total study  duration will depend on 
overall patient tolerability  to the study  drug and response to treatment. It is anticipated that the 
duration of the entire study  (Parts 1 and 2) could be approximately  3years from first patient 
treated to last patient completed.
Part 1
In Part 1, patients will be assigned to treatment according to a 3 +3 dose escalation design 
(Section 3.2 ) and oversight of a Dose Escalation Ste ering Committee (DESC )
(Section [IP_ADDRESS]). 
During the conduct of Part 1, and prior to implementation of Amendment 5, alternative dosing 
schedules are being evaluated at the discretion of the DESC as described below:. 
 120 µg/kg :  Dosing every [ADDRESS_252097] SD after the second 
cycle continue treatment at a reduced dose of 60 µg/kg q6weeks, beginning 6 weeks after Cycle 2 
infusion.  
 150 µg/kg: Dosing every 3 weeks for 2 cycles. Patients with at leas t SD after the second 
cycle continue treatment at a reduced dose of 60 µg/kg q6weeks, beginning 6 weeks after Cycle 2 
infusion.  
 200 µg/kg: Dosing every [ADDRESS_252098] SD 6 weeks after 
Cycle 2, continue treatment at a re duced dose of 60 µg/kg q6weeks, beginning 6 weeks after 
Cycle 2 infusion.
 200 µg/kg: Dosing every [ADDRESS_252099] SD 6 weeks after Cycle 1, 
continue treatment at a reduced dose of 60 µg /kg every [ADDRESS_252100] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 28Part 2
In Part 2, (expansion) , patients will be assi gned to the recommended dose level (s) and 
schedule(s) of ADCT -402identified in Part 1 based on evolving safet y, efficacy and 
pharmacokinetic data .
The population in Part 2 expansion may  be restricted to specific histologies based on both 
signals of activity  and the safet y observed in Part 1.  
Further, dose levels and schedules evaluated in Part 2 may  include but are not limited to the 
following :
A. 90, 120, 150, and/or 200 µg/kg:   Dosing every  3 weeks.
B. 120 µg /kg:  Dosing every 3weeks for 2cycles. P atients with at least SDafter the second 
cycle continue treatment at a reduced dose of 60 µg/kg q6weeks , beginning 6 weeks after Cy cle 2 
infusion.  
C. 150 µg/kg : Dosing every 3weeks for [ADDRESS_252101] SD after the second 
cycle continue treatment at a reduced dose of 60 µg/kg q6weeks , beginning 6 weeks after Cycle 2 
infusion.  
D. 200 µg/kg: Dosing every [ADDRESS_252102] SD6 weeks after 
Cycle 2, continue treatment at a reduced dose of 60 µg/kg q6weeks ,beginning 6 weeks after 
Cycle 2 infusion.
E. 200 µg/kg : Dosing every  [ADDRESS_252103] SD 6 weeks after Cycle1,
continue treatment at a reduced dose of 60 µg /kg every  6weeks beginning 6 weeks after Cycle 1 
infusion.
The continuation of each patient’s treatment will be based on an independent verification of local 
response assessments, unless otherwise approved by  [CONTACT_456].  
The DESC will determine and document thedose levels, schedules, anddisease subtypes to be 
evaluated in Part [ADDRESS_252104] disease assessment until disease 
progression, or initiation of new anticancer treatment . 
After documentat ion of disease progression or start of new treatment, patients will be followed 
(by [CONTACT_210917]) approximately  every  [ADDRESS_252105] survival information.
3.2 Dose Escalation
In Pa rt 1, dose escalation will be conducted according to a 3+3 design (Figure 2). The initial dose 
of ADCT-402 will be 15 µg/kg (Dose Level 1), and t he highest allowed dose will be 300 µg/kg.
The potential dose levels are described in Table 1.
ADC The rapeutics ADCT -[ADDRESS_252106] -402-101 Protocol Amendment 7
Date of Protocol: [ADDRESS_252107] -402
1 15µg/kg 6 150 µg/kg
2 30µg/kg 7 200 µg/kg
3 60µg/kg 8 250 µg/kg
4 90µg/kg 9 300 µg/kg
5 120 µg/kg
The dose -limiting toxicity  (DLT,Section 6.3.1) observation period for dose escalation is 1cycle. 
The first patient enrolled into the study  at 15 µg/kg 
(Dose Level 1) must be observed for [ADDRESS_252108] 6 treated patients, experiences a DLT.
No intra -patient dose escalation is allowed. 
Figur e 2. Schematic Repr esentation for  Dose Escalation (3+3) Design
Abbreviati ons:  DL T, dose -limiting toxicity; MTD, maxi mum tolerated dose; <, less than; ≥ greater than or equal to .
ADC The rapeutics ADCT -[ADDRESS_252109] -402-101 Protocol Amendment 7
Date of Protocol: [ADDRESS_252110] -402 and will 
be decided b y the DESC ( Section [IP_ADDRESS] );PK, and PD evaluations may  also inform decision 
making .
The trial will be continuously  monitored for safet y. If the maximum allowed dose (300 μg/kg) is 
reached and the MTD is not identified, no further dose escalation will be allowed pending a 
safet y analysis and review and accordingl y,an amendment to the protocol.
During Part 1, the DESC may  expand enrollment at any  dose level in which [ADDRESS_252111] 1 patient in the study  has achieved a partial 
response (PR, Section 6.1 ) or better, or if further evaluation of PK or PD data is deemed 
necessary  to characterize pharmacology  in humans. No more than 10 patients in total can be 
treated at an y dose level unless ≥[ADDRESS_252112] achieved a PR or better.
During dose expansion (part 2) , patients will be monitored for safety  using the same DL T criteria 
employ ed during dose -escalation. If during the treatment period, > 30% of patients experience 
safet y events that would meet the criteria that define a DL T in the dose -escalation phase of the 
study , enrollment in the expansion cohort (s)may be paused and the study  data reviewed to 
determine whether additional monitoring or other action (such as alternate dose levels )should be 
evaluated prior to further enrollment.
3.3 Selection of S tudy Population
This is a Phase 1 study  with a sample size of up to 200patients. I t is estimated that 
approximately  90patients will enroll at 11sites in Part 1, and approximately 110 patients will 
enroll at 12 sites in Part 2. Patients will be assigned to a study  treatment only  if they  meet all of 
the inclusion criteria and none of the exclusion criteria.
3.3.1Inclusion Criteria
1.Part 1: Male or female patients, ages [ADDRESS_252113] failed or are intolera nt to established 
therapy , orfor whom no other treatment options are available, in the opi[INVESTIGATOR_210898] .
Refractory  or relapsed B
-cell NHL  (per WHO Classification sy stem ; Swerdlow , 2008) 
defined as: 
Diffuse large B -cell ly mphoma (DLBCL),
Follicular l ymphoma (FL),
Chronic ly mphocy tic leukemia (CLL),
Mantle cell ly mphoma (MCL ),
Marginal Zone B -cell L ymphoma (MZBCL),
Burkitt’ s lymphoma (BL),
Lymphoplasmacy tic lymphoma (W aldenstrom macroglobulinemia [WM]) .
ADC The rapeutics ADCT -[ADDRESS_252114] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 31Part 2: 
Eligible histologic sub -types to be investigated in part [ADDRESS_252115] no other 
treatment options are available, in the opi[INVESTIGATOR_689] .
2.Availability  of formalin
-fixed paraf fin-embedded (FFPE) tumor tissue block . An FFPE block 
from a current biops y is preferred; however, archival tissue taken at initial diagnosis or any 
prior relapse is acceptable . If tissue block is not available, slides from a FFPE block may be 
accept able for eligibility  upon consultation with the Sponsor (Section 6.4 ).
3.Measurable disease, as defined by  [CONTACT_941] 2014 Lugano Classification ( Appendix 12.2). 
4.Eastern Coop
erative Oncology  Group (ECOG) performance status 0 to 2.
5.Absolute neutrophil count (ANC) ≥1000/µL .
6.Platelet count of ≥[ZIP_CODE]/µL .
7.Hemoglobin 
≥9.0 g/dL  without transfusion within the 2 weeks prior to Day  1.
8.Serum /plasma creatinine ≤1.5 mg/dL . If the patient has a creatinine > 1.5mg /dL, a measured 
creatinine clearance must be > 60mL /min as calcula ted b y the Cockcroft and Gault equation
(Cockcroft and Gault 1976 ).
9.Serum /plasma alkaline phosphatase, a lanine aminotransferase (ALT), and aspartate
aminotransferase (AST) ≤2 times the upper limit of normal (ULN); ≤
[ADDRESS_252116] if there is 
liver or bone involvement.
10.Total serum /plasma bilirubin ≤1.5 times UL N (patients with known Gilbert’ s syndrome may  
have a total bilirubin up to ≤3 times UL N).
11.Negative blood or urine beta-human chorionic gonadotropin (β-HCG) pregnancy  test within
7days prior to Day  1for w omen of childbearing potential.
12.Women of childbearing potential* must agree to use a highl y effective** method of 
contraception from the time of giving informed consent until at least [ADDRESS_252117] -402.
*Women of childbearing potential are defined as sexually  mature women who have not 
undergone bilateral tubal ligation, bilateral oophorectomy , or h ysterectom y; or who have not 
been postmenopausal (i.e., who have not men struated at all) for at l east 1 year.
**Highl y effective forms of birth control are methods which achieve a failure rate of less 
than 1% per year when used consistently  and correctly . Highl y effective forms of birth 
control include: Hormonal contraceptives (oral, injectable, pat ch, intrauterine devices), male 
partner sterilization, or total abstinence from heterosexual intercourse, when this is the 
ADC The rapeutics ADCT -[ADDRESS_252118] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 32preferred and usual lifesty le of the patient. Note: The double -
barrier method (e.g., s ynthetic 
condoms, diaphragm, or cervical cap wi th spermicidal foam, cream, or gel), periodic 
abstinence (such as calendar , symptothermal, post -ovulation), withdrawal (coitus 
interruptus), lactational amenorrhea method, and spermicide -only are not acceptable as 
highl y effective methods of contraception.
3.3.2Exclusion Criteria
1.Patients who, in the opi[INVESTIGATOR_689] , have any  option for other treatment for B -cell 
NHL  at the current state of disease. 
2.Active graft -versus -host disease.
3.Autologous or allogenic transplant within the 60 days prior to the Screening visit.
4.Known history  of immunogenicity  or hypersensitivity  to a CD19 antibody .
5.Evidence of m yelod ysplasia or myeloid leukemia by  [CONTACT_5293] , immunostains ,
flow cytometry , or cy togenetics on a bone marrow aspi[INVESTIGATOR_5179] .
6.Known history  of posit ive serum human ADA.
7.Active autoimmune disease (e.g., rheumatoid arthritis, sy stemic progressive sclerosis 
[scleroderma], sy stemic lupus ery thematosus, Sjögren's s yndrome, autoimmune vasculitis 
[e.g., W egener's granulomatosis]); motor neuropathy  considered of autoimmune origin (e.g., 
Guillain -Barré s yndrome and my asthenia gravis); other CNS autoimmune disease (e.g., 
poliomy elitis, multiple sclerosis). Known seropositive for human immunodeficiency  (HIV) 
virus, hepatitis B surface antigen (H BsAg), or antibody to hepatitis C virus (anti- HCV) with 
confirmatory  testing and requiring anti -viral therapy . 
Note: Testing is not mandatory  to be eligible. Testing for HCV  should be considered if the 
patient is at risk for having undiagnosed HCV  (e.g., history  of injecti on drug use).
8.History  of Steven's Johnson's s yndrome ortoxic epi[INVESTIGATOR_210899] .
9.Pregnant or breastfeeding women.
10.Significant medical comorbidities, including uncontrolled hy pertension (diastolic blood 
pressure greater than 1 15 mm Hg ), unstabl e angina, congestive heart failure (greater than 
[LOCATION_001] Heart Association class II), severe uncontrolled ventricular arrhythmias, or 
electrocardiographic evidence of acute ischemia, poorly  controlled diabetes, severe chronic 
pulmonary  disease, coronary  angioplasty ,or my ocardial infarction within 6 months prior to 
screening , or uncontrolled atrial or ventricular cardiac arrhythmias.
11.Use of any other experimental medication (s)within 14 day s or 5 half -lives but in no case less 
than 14 day sprior to start of study  treatment on Cy cle 1, Day 1.
12.Steroid use equivalent to greater than 20 mg of prednisone within 4 weeks 
(28 day s) prior to 
Day 1, except for the use of short course s ystemic corticosteroids ( ≤ 7 day s), with a was h-out 
period of [ADDRESS_252119] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 3313.Major surgery , chemotherapy , systemic therapy  (excluding steroids
; and any  targeted small 
molecules or biologics), ), radiotherap y, within 14daysor 5 half -lives (whichever is shorter) 
prior to Cycle 1, Day 1 treatment , except if approved by  [CONTACT_1034] .
14.Failure to recover (to Common Terminology  Criteria for Adverse Events [CTCAE] Grade 0 
or Grade 1) from acute non hematologic toxicity (except all grades alopecia or grade 2 or 
lower neuropath y), due to previous therap y, prior t o Screening.
15.Congenital long QT  syndrome ,or a corrected QT c interval of ≥450 ms,at the Screening visit
(unless secondary  to pacemaker or bundle branch block).
16.Active second primary  malignancy  other than non -melanoma skin cancers, non metastatic 
prostate c ancer , in situ cervical cancer , ductal or lobular carcinoma in situ of the breast , 
orother malignancy  that the S ponsor ’smedical monitor and Investigator agree and document 
should not
be exclusionary .
17.Any other significant medical illness, abnormality , orcondition that would, in the 
Investigator ’s judgment, make the patient inappropriate for study  participation or put the 
patient at risk .
ADC The rapeutics ADCT -[ADDRESS_252120] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 344Study Procedures
4.1 Procedures by S tudy Day
The following procedures will be performed during the study .Timings for samp
le collections 
and procedures are provided in Appendix 12.1.
4.1.1 Screening Period (Day –28 to –
1)
Thefollowing procedure swill be performed within 28 days prior to the Day  1visit of Cy cle1, 
unless otherwise specified:
A signed and dated I nstitutional Review Board (IRB) /I ndependent E thics Committee (I EC)
approved informed consent form (ICF) obtained prior to performing an y study evaluations.
Results (e .g., from laboratory  tests or radiographic evaluations, etc.) obtained prior t o the 
date of informed consent but within the allowed timeframe for screening may  be used for 
determination of patient eligibility  only if obtained as part of the patient’ s standard of care .
Demograph
ic characteristics.
Medical history  (to include a comple te history  of all sur geries and significant diagnoses and 
all cancer treatment [including surgery , radiation therapy , chemotherap y, etc.]).
Blood or urine 
β-HCG pregnancy  testing(women of childbearing potential only) .
Physical examination including whole bod y skin assessment . The w hole body  skin 
assessment does not have to be performed b y a dermatologist . However , any unexplained 
lesion 
is to be referred toa dermatologist for further evaluation and skin biopsy ,ifclinicall y 
warranted.
Vital signs (arterial blood pressure, heart rate, respi[INVESTIGATOR_2842], bod y temperature), height and 
weight measurements
.
ECOG performance status .
 
 
 
 
Disease assessment :Positron emission tomography  -computed tomography  (PET -CT) and 
diagnostic CT  of the neck/chest/abdomen/pelvis and ot her areas of known disease or newl y 
suspected disease with a clinical examination for ly mphoma . Contrast should be used unless 
contraindicated. Magnetic resonance imaging (MRI ) is permitted if 
diagnostic CT is 
contraindicated. The same assessments methods used at Screening which identify  sites of 
disease should be used uniformly  for all subsequent assessments. 
Note: PET-CT is onl y required at screening for 18F -fluorodeoxy glucose (FDG) avid, nodal 

ADC The rapeutics ADCT -[ADDRESS_252121] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 35lymphomas (defined as per the Lugano Classification criteri a as essentially  all eligible 
histologies except small ly mphocy tic lymphoma, ly mphoplasmacy tic 
lymphoma/W aldenstrom’ s macroglobulinemia, mycosis fungoides, and marginal zone NHLs, 
unless there is a suspi[INVESTIGATOR_210900]). If PET -CT examina tion is negative 
at Screening, subsequent PET
-CT is not required.  If PET- CT is positive, subsequent 
diagnostic CT  and MRI are not needed unless clinically  indicated.
Hematology , coagulation panel, biochemistry , and ur inaly sisparameters .
12-lead electroca rdiogram ( ECG ) .
Collection of adverse event ( AE) information .
Collection of information on medication sused(including prescription or over -the-counter 
medication, herbal or naturopathic products ) within the 14daysprior to the Day 1visit.
4.1.[ADDRESS_252122] -402 infusion (unless otherwise 
indicated) at each cy cle, unless otherwise specified .  
Blood or urine 
β-HCG pregnancy  test required if the pregnancy  test was obtained >7 days 
prior to Day  1(every other cy cle).
Physical examination including whole bod y skin assessment , unless an assessment was 
performed within 3 day s prior to Day  1.
Vital signs:  On Day  [ADDRESS_252123] -402 infusion, every 30 minutes during the infusion , at the end of infusion , and at 1, 3, 
and 6 hours after the end of infusion. If no clinically  significant changes occur during Cycles 
1 and 2, vital sign measurements are to be obtained prior to infusion start and en d of infusion 
for all subsequent infusions. If clinicall y significant changes in vital signs are observed at 
Cycle 1 and/or [ADDRESS_252124] -402 infusion for all subsequent 
cycles.
Weight .
ECOG performance status .
Samples for hematology , coagulation panel, biochemistry  parameters, will be measured prior 
to dosing unless the last sample was collected:
o<24hours before the start of ADCT -402 infusion on Day  1 of C ycle 1, or
o<[ADDRESS_252125] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 36Sample collection for additional renal fun ction studies .
Sample collection for urinaly sis
Prior to dosing unles
s the last sample was collected:
o<[ADDRESS_252126] -402 infusion on Day  1 of C ycle 1, or
o<[ADDRESS_252127] -402 infusion on Day  1 of C ycle 2 and subsequent
cycles.
Disease assessment:
Patients Initially  Treated Every  [ADDRESS_252128] 
cycle (i .e., C ycles 8, 1 1, 14, etc.), until disease prog ression, or more frequently , 
ifclinica lly indicated.
oPatients who initially  follow a 
three -week dose schedule and then transition to a six -week 
schedule following C ycle [ADDRESS_252129] disease assessments ~6 weeks after C ycle 1
Day1, and ~[ADDRESS_252130] e very 12 weeks. It is understood that there will be a ± 6 day  
window for restaging of these patients.
oFor patients in Part 2: T reatment continuation will require independent verification of the 
local response assessment unless otherwise approved by  [CONTACT_78269].  
In case of dose delay s, please refer to Section 6.[ADDRESS_252131] is not required.
12-lead ECG (C ycles 1 and 2) before the start of the ADCT -402 infusion, within 30 minutes 
of the end of infusion, and at 
3 hours (± 30 minutes) and 24 (± 2.4) hours after the end of 
infusion. For Cycle [ADDRESS_252132] -402 infusion.
Sample collectio n for central laboratory  anal ysis of ADA  (all cy cles) .
Sample collection (Cycles 1 and 2) for central laboratory  analy sis of PK parameters before 
the start of the ADCT -[ADDRESS_252133] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 37 
 
Collection of AEinformation .
Collection of concomitant medication information .
Premedication administration
,if appli cable ( Section 5.2).
ADCT -
402administration.
4.1.3Day 2 (Cycles 1 and 2)
The following procedures will be performed 24 hours (± 10%) after the end of the ADCT-402 
infusion:
12-lead ECG .
Vital signs
Sample collection for central laboratory  anal ysis of PK parameters.
Collection of AE information.
Collection of concomitant medication information.
4.1.4
Day 3 (Cycles 1 and 2)
The following procedures will be performed 48 hours (± 10%) after the end of the ADCT-402 
infusion:
Vital signs.
Sample collection for central labor atory  anal ysis of PK parameters.
Collection of AE information.
Collection of concomitant medication information.
4.1.5Day 5 (Cycles 1 and 2)
The following procedures will be performed 96hours (± 1 day )after the en d of the ADCT -402 
infusion:
Sample collection for central laboratory  anal ysis of PK parameters.
Vital signs.
Collection of AE information.
Collection of concomitant medication information.
4.1.6 Day 8 (± 2 days )of Each Cycle
Physical examination (Cycles 1 and 2) including whole body  skin assessment.

ADC The rapeutics ADCT -[ADDRESS_252134] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 38Weight 
Vital sign
s.
Hematology and b iochemistry parameters.
Urinaly sisand sample collection for a dditional renal function studies .
Sample collection for central laboratory  anal ysis of PK parameters ( Cycles 1 -4).
Collection of AE information .
Collection of concomitant medication information .
4.1.7 Day 15 (± 2 days) of Cycle s 1 and 2
The Day  15 visit will be conducted during C ycles 1 and 2 only; the following procedures will be 
performed at this visit:
Physical examination including whole bod
y skin assessment.
Weight.
Vital signs .
Hematology and b iochemistry parameters.
Urinaly sisand sample collection for a dditional renal function studies .
Sample collection for central laboratory  anal ysis of PK parameters.
Collection of AEinformation .
Collection of concomitant medication information .
4.1.8 Day 28 (± 3days) 
For patients who have transitioned to a reduced dosing frequency (see Section 3.1) this visit will 
be required for Safet y/PK Monitoring. Assessments required for Safet y/PK M onitoring are 
indicated below .  For patients in Part 1 this visit will be done approximately  21 day s after 
infusion.  
Physical examination 
Vital signs
Weight
ECOG
12-lead ECG
Sample collection for h ematology , coagulation panel, and biochemistry  parameter s
Sample collection for u rinaly sis
ADC The rapeutics ADCT -[ADDRESS_252135] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 39Sample collection for additional renal function studies.
Sample collection for central laboratory  anal ysis of PK parameters and ADA .
Collection of AE information
Collection of concomitant medication information
4.1.9 End ofTreatment Visit
The following procedures will be performed within 30days after study  treatment discontinuation
and prior to initiation of new anticancer treatment :
Physical examination including whole bod y skin assessment .
Weight and v
ital sign s.
ECOG perfo rmance status.
Disease assessment s:
oPatients who alread y have documented objective disease progression do not need tohave 
assessments repeated.
oPatients who do not already  have documented objective disease progression will have 
assessments performed at the end of t reatment visit if the most recent disease assessment 
was >
9 weeks prior to the end of treatment visit.
Blood or urine pregnancy  test
Hematology ,coagulation panel ,and biochemistry  parameters.
Urinaly sisand sample collection for a dditional rena l function studies.
12-lead ECG .
Sample collection for central laboratory  anal ysis of PK parameters and ADA .
 
Collection of AEinformation
Collection of c oncomitant medication information .
When EOT  coincides with a scheduled visit, the scheduled visit will become EOT .
4.1.[ADDRESS_252136] a blood sample taken for assessment of PK and ADA at 12 (±1) weeks 
after their last dose of ADCT
-402, unless a new anticancer treatment has been initiated.
Blood Sample Collection and Adver se Event Monitoring During Long -Term Follow -up
Patients who test positive for ADAs may be requested to supply  additional ADA  samples.

ADC The rapeutics ADCT -[ADDRESS_252137] -402-101 Protocol Amendment 7
Date of Protocol: [ADDRESS_252138] dose of 
study  drug 
or initiation of new anticancer treatment (see Section [IP_ADDRESS] ).
4.1.[ADDRESS_252139] survival information.
4.2 Withdrawal of Patients from the S tudy
The duration of the stud y participation for each patient is defined a s the time from the date of 
signed written informed consent through the completion of the follow -up period or withdrawal of 
consent .
4.2.1 Reasons for Withdrawal /Discontinuation
Patients may withdraw from the study  at an y time and for an y reason without prejudic e to 
their
future medical care b y the Investigator or others at the study  site.
A patient may be withdrawn from treatment with ADCT -
402for any  of the following reasons:
Disease progression .
AE.
Withdrawal of consent .
Major protocol deviation .
Required t reatment delay >21days (except in case of potential patient benefit , which must be 
approved by[CONTACT_941] S ponsor) .
Following a dose delay due to toxicity , if the same toxicity  recurs after second dose reduction, 
study  drug must be discontinued permanently .
Non-compliance, including lost to follow -up.
Pregnancy .
Other (e.g., development of contraindications with use of the 
study  drug) .
The Investigator de termine sthat it is in the best interest of the patient to discontinue the 
patient ’s participation in the study .
Discontinuation of the study  by [CONTACT_941] S ponsor .
ADC The rapeutics ADCT -[ADDRESS_252140] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 41Death.
Patients experiencing other significant toxicities must be immediately  and permanentl y 
withdrawn from treatment with ADCT -
402as follows:
Any patient who experiences a G rade 3 or higher hypersensitivity (Appendix 12.3) reaction , 
regardless of premedication, during an y cycle of treatment . 
Any patient who experiences a recurrent G rade 3 or 4 toxicity , excluding hematological 
toxicity .
Any patient who requires a dosing delay  >21 consecutive day s from the planned Day 1 
dosing at an y time during treatment (except in case of potential patient benefit, which must 
be approved b y the Sponsor) .
4.2.2 Handling of Withdrawals
The Investigator will confer with the Sponsor if a patient experienc es a serious or intolerable AE. 
If a patient discontinues from the study
 because of an AE, the patient will be followed to 
satisfactory  resolution, until the I nvestigator deems the event to be chronic or not clinicall y 
significant, or until the patient is considered to be stable ( Section [IP_ADDRESS]).
For each patient who discontinues study  treatment and withdraws from the study , the 
Investigator will record the reason(s) for discontinuation on the relevant page of the electronic 
case report form (eCRF). Whenever possible, each patient who discontinues study  treatment will 
undergo an EOT visit and all EOT assessments ( Section 4.1.9). Patients who fail to return for 
final assessments are to be contact[INVESTIGATOR_530] b
y the investigative site. Following a minimum of 2 
documented unsuccessful telephone calls, the investigative site will send a registered letter to the 
patient in a final attempt to ensure protocol compliance.
Note: Once discontinued from the study , for any  reason, pati ents are not permitted to be 
re-enrolled into the study .
4.2.[ADDRESS_252141] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 425Study Treatments
5.1 Method of Assigning Patients to Treatment Gr oups
In Part 1 (dose escalation), patients will receive an IV infusion of ADCT -402  on Day  1 of each 
3-week (21 -day) cycle. The first patient receiving the first dose of ADCT -[ADDRESS_252142] allowed dose (300 μg/kg) is 
reached and the MTD is not identified, no further dose escalation will be allowed, pending a 
safet y analysis and an amendment to the protocol.
In Part 2 (expansion), patients will be assigned to the recommended dose level (s)andschedule(s) 
of AD CT-402 identified in Part 1 by  [CONTACT_210918]. Once the recommended Part 2 dose (s) and 
schedule(s) is/aredetermined, patients receiving lower or higher dose levels of ADCT
-402 may  
be offered continued treatment at the recommended dose(s) and schedule(s).
5.2 Prophy lactic Treatments for Hypersensitivity
If 1 patient experiences a Grade 2 or higher (Appendix 12.3) infusion -related hypersensitivity 
reaction at an y time during Part 1 (dose escalation), all subsequent patients must receive 
prophy lactic treatment, as described below or as per the institution’s standard of care, to reduce 
the risk of h ypersensitivity reactions.
On Day  [ADDRESS_252143] infusion may  be defined as “immediately  before sleepi[INVESTIGATOR_007]” and “immediatel y 
after waking up”.
On Day  [ADDRESS_252144] -402 infusion.
On Day  1 of each cy cle, patients will be given 50 mg of ranitidine (or equivalent) IV  at [ADDRESS_252145] -402 infusion.
For [ADDRESS_252146] treatment center protocols. Medications for the treatment of 
severe h ypersensitivity  reactions, including anaphy laxis, should be available for immediate use.
If a patient experiences a Grade 1 or 2 h ypersensitivity  reaction (Appendix 12.3) , the following 
medications (or equivalent) shoul d be administered for [ADDRESS_252147]
-402 infusion:
Ranitidine 150 mg orally , 2 times per day .
Diphenhy dramine hy drochloride 50 mg orally , 3 times per day .
Any patient who experiences a Grade 3 or higher hy persensitivity  (Appendix 12.3) reaction 
should be discontinued from the study  and immediately  treated according to institutional 
ADC The rapeutics ADCT -[ADDRESS_252148] -402-101 Protocol Amendment 7
Date of Protocol: [ADDRESS_252149] be carefully  
observed after the treatment. Additional therap y,as per the institution’s standard of care, should 
also be followed.
5.3 Treatments Administered
In Part 1 (dose escalation), each patient will be assigned a dose level and schedule as described 
in Section 3.1 and Section 3.2. I n Part 2 (expansion), all patients will be assigned to the 
recommended dose level (s) and schedule(s) of ADCT-[ADDRESS_252150] cy cle, the infusion duration may  be shortened to 30 minutes for 
subsequent cy cles, on an individual patient basis, at the Investigator’s discretion. Variations in 
infusion times due to minor differences in IV bag overfill/underf ill and the institution’s 
procedure for flushing chemotherap y lines will not result in protocol deviation.
Prophy lactic antiemetic medications, electrol yte supplementation, and other standard supportive 
care measures may  also be administered according to standard treatment center protocols, or as 
in Section 5.2 and Section 5.9.2 .
Although the study patient population has a low risk for development of tumor lysis syndrome 
(TLS) compare d to patients with acute disease ( Cairo, 2010), patients should be observed for 
development of TLS and treated according to standard treatment center protocols .
Because of non- clinical observations related to nephropathy , adequate patient hy dration (e.g., 8
to 10 glasses of water or equivalent per day ) is recommended for patients receiving ADCT - 402.
Additionally , because n ewor worsening edema and / or new or worsening pleural ef fusion have 
been observed
, patients are advised to mo nitor their weight on a dail y basis ( Section 6.3.8 and 
5.9.2) 
As non
-clinical testing indicates testicular toxicity (atroph y with reduced spermatogenesis) , male 
patients are advised to consider cry opreservation of sperm prior to treatment with ADCT -402, 
where applicable .
Available pre -clinical data on ADCT -[ADDRESS_252151] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 44However , skin rash has been reported in the ADTC 402 -101 study , as well a s with another 
investigational agent containing the same p yrollobenzodiazepi[INVESTIGATOR_210901] ( Rudin, 2016 ).  The 
rash has been limited to areas at risk for sun exposure, it is therefore recommended that 
precautions are taken to avoid pr olonged exposure of skin to direct sunlight. 
5.[ADDRESS_252152]- 402 dosing for up to 21 day s for any  patient who 
experiences a protocol
-defined DLT after C ycle 1 (the defined DLT observation period) . Atthe 
discretion of the Investigator, the dose may  also be delay ed for up to [ADDRESS_252153] -402 after suspension is at the 
discretion of the Investigator, based on assessment of the patient’s clinical condition and whether 
or not the patient is deriving potential clinical b enefit from treatment with ADCT -402. Following 
recovery  to Grade [ADDRESS_252154] -402 may  resume at the 
Investigator’s discretion.
Patients who re sume treatment following a dose delay  may , at the discretion of the DESC, have 
their dose of stud y drug reduced b y 50%. If toxicity occurs again at the reduced dose, the patient 
will be discontinued from the study .  
During part 2, dose delay due to toxici ty may  extend bey ond 21 day s at the discretion of the 
investigator , in consultation with the Sponsor, based on assessment of the patient’s clinical 
condition and whether or not the patient is deriving potential clinical benefit from treatment with 
ADCT
-402. When dosing is resumed, the dose may  be decreased by 50% at the discretion of the 
Investigator , in consultation with the Sponsor .
Ifthe dose is reduced and the toxicity  recurs, the dose will be further reduced b y 50%.
If toxicity  recur safter second dos
e reduction, study  drug must be discontinued permanently .
If dose is held for six weeks or more, restaging scans must be done prior to restarting dosing to 
rule out disease progression.
5.[ADDRESS_252155] -402 to the study  sites. 
The following drug supplies will be used in the study : 
Product Supplied As:
ADCT -402 10 -mL single -use glass vial with overfill to allow for up to 3.2 mL  to 
deliver a total of 16 mg per vial (ov erfill deliverable volume 3.5 mL  
at 5 mg/mL). (equivalent to [ADDRESS_252156] -402)
5.5.[ADDRESS_252157]-402 is a sterile formulation containing PBD- conjugated RB4v1.2 (DAR ≥1), RB4v1.2 
(DAR = 0), and SG3249. I t is provided pre -formulated in [ADDRESS_252158] - 402 per vial (deliverable volume 3.2 mL  at 5 mg/mL).
ADC The rapeutics ADCT -[ADDRESS_252159] -402-101 Protocol Amendment 7
Date of Protocol: [ADDRESS_252160] be stored in a secure area (e.g., a locked cabinet). ADCT -402 should be 
protected from light and stored frozen ( –65°C or below). ADCT -[ADDRESS_252161] -402 will be 
removed from the vial with a sy ringe and diluted into a 50 mL  IV bag containing 5% dextrose in 
water (D5W) /Glucose. The amount of the product to be diluted will depend on the dose level and 
the body  mass of the pati ent. Once the ADCT -[ADDRESS_252162] supportive care measures for the 
management of any observed toxicity  should be applied.
5.8 Treatment C ompliance
Administration of the study  treat ments will be performed b y the I nvestigator or a qualified 
designee; therefore, compliance will be verified by  [CONTACT_210919]. 
5.[ADDRESS_252163] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 46over-the-counter medications. Any  changes in concomitant medications will also be recorded in 
the pa tient’s eCRF .
5.9.1 Prohibited During S tudy
Other anticancer therap y with the exception of hormonal therap y for maintenance treatment 
of breast and prostate cancer .
Radiation therap y is prohibited during the first cy cle of therap y.After the first cy cle, 
radiati on is permitted for palliative use only  if documented radiographic disease progression 
is ruled out first.
Other investigational agents
.
Chronic treatment with corticosteroids (prednisone ≥12.5 mg/day  or dexamethasone
≥2mg/day , excluding inhaled steroids ).
Live vaccines .
5.9.2 Permitted During S tudy
After confirmation and documentation of eligibility , supportive care treatments 
(tran sfusions, etc.) can be prescribed as medicall y appropriate.
Hematopoietic growth factors are permitted as per American Societ y of C linical Oncology  
guidelines (Smith, 200 6); however, proph ylactic use of growth factors is not allowed during the 
first treatment cy cle.
Ifa Grade 2 or higher infusion -related h ypersensitivity  
(Appendix 12.3) reaction isobserved in 
1patient at an
y time during Part [ADDRESS_252164] receive proph ylactic 
treatment ( Section 5.2).
Concomitant steroid use is permitted as follows:
Repla cement doses of steroids for patients with adrenal insuf ficiency
Intranasal, inhaled, topi[INVESTIGATOR_8826], or local steroid injections ( e.g., intra-
articular injection)
During Part 1, the DESC agreed to evaluate the potential for the addition of dexamethasone to 
mitigate toxicit y.  The recommendation was communicated (February  2017) as follows: 
Dexamethasone 8 mg PO BID
Day -1 (day  prior to dosing) [if possible]
Day 1 (day  of dosing, pre -dose)
Day 2 (day  after dosing)
It is further recommended that patients i n Part [ADDRESS_252165] receive 
dexamethasone as follows:
Dexamethasone 4 mg PO BID the day  before IP administration (if possible) , the day  of IP  
administration (given at least 2 hours prior to IP  administration, if not given the day  before) , 
ADC The rapeutics ADCT -[ADDRESS_252166] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 47and the day  after IP  administration (W eek 1/Day  1 of each cy cle onl y, regardless of treatment 
schedule).
In addition, spi[INVESTIGATOR_8407], at standard doses, may be instituted at any time for patients with 
weight gain great er than 1 kg (2.2 pounds ) from Cycle 1 Day 1,new or worsenin
g edema and/or 
new or worsening pleural effusion.  The dose of spi[INVESTIGATOR_210902] y 
indicated.  Additional diuretic support may  be added if there is further increase in weight, edema 
or pleural ef fusion.
Any concomitant medication deemed necessary  for the welfare of the patient during the study  
may be given at the discretion of the Investigator .
ADC The rapeutics ADCT -[ADDRESS_252167] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 486Study Assessments and Procedures
Patients will under go the procedures at the time points specified in schedule of events
(Appendix 12.1) .
6.[ADDRESS_252168] 2evaluations (6 weeks [end of 
Cycle 2 ±1 week] and12 weeks [end of C ycle 4 ±1 week] ), and every  third cy cle
(every  9 weeks [e.g., end of Cy cles 7, 10, 13, etc., ±1 week]
) thereafter until progression ,or 
more frequently ,if clinically  indicated . 
Patients I nitially  Treated Every  3 weeks 
To be conducted within [ADDRESS_252169] 
cy
cle (i.e., C ycles 8, 1 1, 14, etc.), until disease progression, or more frequently , if clinicall y 
indicated.
Patients who initially  follow a three week dose schedule and then transition to a six week 
schedule following cy cle [ADDRESS_252170] disease assessments ~6 weeks after C ycle 1 Day1, 
~12weeks after C ycle [ADDRESS_252171] every  12 weeks.
Patients Initially  Treated Every  6 weeks 
For patients who have reduced dosing frequency  and are following a [ADDRESS_252172] every  12 weeks. I t is understood that there will be a ± 6 day  window 
for restaging of these patients.
For patients in Part 2: T reatment continuation will require independent verification of the local 
response assessment unless otherwise approved by [CONTACT_456] .  
Assessments may be performed within ± [ADDRESS_252173] -402 dosing (onl y if the 
interval from last scan is ≥ 6/9 /12weeks, as applicable) to rule out disease progression.
The patient’ s response to treatment will be determined by  [CONTACT_210920] 
(CR), partial response (PR), stable disease (SD), or progressive d isease (PD) , based onthe 2014 
Lugano Classification Criteria (Appendix 12.2). Images will be obtained according to local site 
imaging requirements andmay be required to be submitted for a central/independent r eview .
Submission instructions for the central/independent review will be provided in a separate manual.
6.2 Pharmacok inetic and Pharmacodynamic Assessments
Blood (5 -mL draw) samples will be collected for assessment and will be processed according to 
the instr uctions provided by  [CONTACT_210921]. All PK and 
ADC The rapeutics ADCT -[ADDRESS_252174] -402-101 Protocol Amendment 7
Date of Protocol: [ADDRESS_252175] -402 (total antibody ; DAR ≥0), PBD -conjugated antibody  (DAR ≥1), 
and free warhead SG3199 will be assessed b y a central laboratory. Additional PK blood samples 
will be collected, at the discretion of the Investigator, during an y visit where toxicity  is observed. 
A PK 
and ADA sample will also be collected concurrentl y with an y other blood draw to assess 
safet y (e.g., Unscheduled Visit), if possible. All PK samples will be evaluable as long as actual 
collection times are recorded.
To understand the metabolic disposition of ADCT
-402 in humans, samples remaining after PK 
analysis is complete may be pooled among patients for potential metabolite identification.
The PK profile will include determination of: maximum concentration ( Cmax), time to Cmax(Tmax), 
area under the con centration -time curve from time zero to the last quantifiable concentration 
(AUC 0-last), area under the concentration -time curve (AUC) from time zero to the end of the 
dosing interval (AUC 0-τ), area under the concentration -time curve from time zero to infi nity 
(AUC 0-∞), accumulation index (AI), volume of distribution at steady- state (V ss), mean residence 
time (MRT), terminal elimination phase rate constant (λ z), terminal half-life ( T1/2), clearance 
(
CL), and volume of distribution ( Vz).
6.2.2 Pharmacodynamic and Other Assessments
The following pharmacody namic /exploratory  assessments will be performed at vary ing 
timepoints in the study :
 
Level of ADAs against ADCT -402 in serum.
 
6.3 Safety and Tolerability Assessments
Safety  will be assessed based onAEs, SAEs, periodic 12- lead ECG recordings, ph ysical 
examinations, vital signs measurements, ECOG performance status, andhematology , coagulation 
panel, biochemistry ,pregnancy  testing (for women of child-bearing potential) and urinal ysistest 
results . Adverse events will be graded according to CTCAE version 4.0. A schedule of safet y 
assessments is provided in Appendix 12.1.

ADC The rapeutics ADCT -[ADDRESS_252176] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 506.3.1 Definition of Dose -
Limiting Toxicities
A DLT is defined as an y of the following events ,except those that are clearly  due to underl ying 
disease or extraneous causes .
A hematologic DL Tis defined as :
oGrade 3 or 4 febrile ne utropenia or neutropenic infection .
oGrade 4 neutropenia lasting >7 day s.
oGrade 4 thrombocy topenia.
oGrade 3 thrombocy topenia with clinically  significant bleeding ,or Grade 3 
thrombocy topenia requiring a platelet transfusion.
oGrade 4 anemia .
A non-hematologi c DL Tis defined as :
oGrade 4 tumor l ysis syndrome (Grade 3 TLS will not constitute DL T unless it leads to 
irreversible end -organ damage).
oGrade 3 or higher AE (including nausea, vomiting, diarrhea, and electrol yte imbalances 
lasting more than 48 hours desp ite optimal therapy ; excluding all grade of alopecia).
oGrade 3 
orhigher hypersensitivity  (Appendix 12.3) reaction (regardless of premedication ) .
oGrade 2 or higher skin ulceration.
The DLT period for dose escalation will be 1 cycle.
[IP_ADDRESS] Safety Oversight by [CONTACT_210910]
A DE SC will be responsible for safet y monitoring and overall supervision of the study . 
Membership of the DESCwill include:
Medical monitor(s)/Pharmacovigilance representative(s) ( Sponsor and/or designee)
Investigator(s) from each participating site
Biostatistician(s)
Ad-hoc members (e.g., project manager , study  coordinators, regulatory  representatives, etc.)
In general, the DESC will make any substantial decision sregarding the conduct of the study , 
such as :
Monitor the safet yof the study  and review its progress at monthly intervals or more frequent 
intervals as required .
D
etermine dose levels to be administered and the MTD based on assessment of safet y 
findings and determination of DL Ts.
Appr ove an y amendments or administrative changes to the protocol , when required .
ADC The rapeutics ADCT -[ADDRESS_252177] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 51Each DESC meeting and the decisions made will be documented in writing and provided to all 
participating DESC members and Investigator s
. Meeting documents may  be submitted to 
IRBs/IECs or competent authorities according to institutional or local requirements .
The DESC will be maintained d uring 
Part 2 ( expansion )of the study to continue to monitor and 
evaluate patient safet y.
6.3.2 Adverse Events
[IP_ADDRESS] Definitions of Adverse Events
The Investi gator is responsible for reporting all AEsthat are observed or reported during the 
study , regardless of their relationship to study  drug or their clinical significance.
An AEis defined as an y untoward medical occurrence in a patient enrolled into this st udy 
regardless of its causal relationship to study  drug. Patients will be instructed to contact [CONTACT_210922] y time after ICF signature [INVESTIGATOR_132037].
A treatment -emergent AE (TEAE) is defined as any  event not present before exposure to study  
drug or an y event alread y present that worsens in either intensity  or frequency  after exposure to 
study  drug.
A serious adverse event (SAE )is defined as an y event that results in death, is immediately  life 
threatening, requires inpatient hospi[INVESTIGATOR_178665], results 
in persistent or significant disability /incapacit y, or is a congenital anomal y/birth defect. 
Hospi[INVESTIGATOR_210903].
Important me dical events that may  not result in death, are life threatening, or require 
hospi[INVESTIGATOR_210904] s when, based upon appropriate medical judgment, the 
event may jeopardize the patient ormay require medical or surgical intervention to preven t any 
of the outcomes listed in this definition. Examples of such medical events include allergic 
bronchospasm requiring intensive treatment in an emergency  room or at home, blood dy scrasias 
or convulsions that do not result in inpatient hospi[INVESTIGATOR_059], o r the development of drug 
dependency  or drug abuse.
[IP_ADDRESS] Eliciting and Documenting Adverse Events
All AEs will be assessed from the time the patient signs the ICFuntil 84days (12 weeks) after 
the last dose of study  drug or initiation of new anticancer treatme nt.
Any SAEsthat occur more than [ADDRESS_252178] been hospi[INVESTIGATOR_057], had 
any accidents, used any  new medications, or changed concomitant medication regimens (both 
prescription and over-the-counter medications).
In addition to patient observations, 
AEswill be documented from any  data collected on the AE
page of the eCRF (e.g.,clinically  significant changes in laboratory  values, phy sical examination, 
ADC The rapeutics ADCT -[ADDRESS_252179] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 52ECG changes , etc. ) or identified from review 
of other documents that are re levant to patient
safet y.
[IP_ADDRESS] Reporting Adverse Events
All AEsreported or observed during the stud y will be recorded on the AEpage of the eCRF. 
Information to be collected includes drug treatment, dose, event term inology , date of onset, 
CTCAE version 4.0assessment of severit y and relationship to study  drug, date of resolution of 
the event, seriousness, any  required treatment or evaluations, and outcome. With the exception of 
disease progression, AEs resulting from concurrent illnesses, reactions to concurren t illnesses, 
and reactions to concurrent medications also must be reported. All AEs will be followed to 
adequate resolution.
Any AEthat meets SAE criteria ( Section [IP_ADDRESS]) must be reported to the contract rese arch 
organization ( CRO )immediatel y (i.e., within [ADDRESS_252180] learn 
about the event )
. The following contact [CONTACT_160523]:
[IP_ADDRESS] Assessment of Severity
Adverse events are graded according to CTCAE version 4.0.For events not included in the 
CTCAE criteria, t he severity  of the AEis graded on a scale of [ADDRESS_252181] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 53Table 2.Definition of Severity Grades for  Common T erminology Criteria for  Adverse 
Events 
(CTCAE) 
Grade Definition
1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated
2 Moderate; minimal, local or noninvasive intervention indicated; limiting 
age-appropriate instrumental ADLa
3 Severe or medically significant but not immediately life threatening; hospi[INVESTIGATOR_210905]; disabling; limiting self-care ADLb
4 Life-threatening consequences; urgent intervention indicated
5 Death related to adverse event
aInstrumental activities of daily living (ADL) refer to preparing meals, shoppi[INVESTIGATOR_3112], 
using the telephone, managing money, etc.
bSelf-care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, 
and not bedridden.
Changes in the severit y of an AEshould be documented to allow an assess ment of the duration 
of the event at each level of intensity  to be performed. Adverse events characterized as 
intermittent do not require documentation of onset and duration of each epi[INVESTIGATOR_1865].
[IP_ADDRESS] Assessment of Causality
The Investigator ’s assessment of an AE ’srelationship to study  drug is part of the documentation 
process, but it is not a factor in determining what is or is not reported in the eCRF .All adverse 
events, regardless of assessment of causalit y, are reported in the eCRF.
All SAEs considered at least possibly  related to the study  drug will be considered unexpected;
and therefore ,reported as Suspected Unexpected Serious Adverse Reactions ( S[LOCATION_003]Rs).
[IP_ADDRESS] Follow -Up of Patients Reporting Adverse Events
All AEs must be reported in detail on the appropriate page of the eCRF and followed to 
satisfactory  resolution ,until the Investigator deems the event to be chronic or not clinicall y 
significant , oruntil the patient is considered to be stable.
6.3.[ADDRESS_252182] be rep orted as described 
for reported AEs in Section [IP_ADDRESS], upon learning of its occurrence. The pregnancy must be 
followed to determine outcome (including spontaneous miscarriage, elective termination, normal 
birth, or congenital abnormality ) and status of mother and child , even if the patient was 
discontinued from the study . The outcome of the pregnancy  will be reported on the Pregnancy  
Outcome Form. Spontaneous 
miscarriage s must be reported as an SAE.
ADC The rapeutics ADCT -[ADDRESS_252183] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 54Any SAE occurring in association with a pregnancy that is brought to the Investigator ’s attention 
after the 
patient has completed the study and considered b y the Investigator as possibly related to 
the study  treatment must be promptly  reported (Section [IP_ADDRESS]).
6.3.[ADDRESS_252184] results are to be recorded as AEs or SAEs per 
CTCAE version 4.0.
[IP_ADDRESS] Hematology
Complete blood count (CBC) include sWBC with [ADDRESS_252185] include partial thromboplastin time (PTT) and 
International Normalized Ratio ( INR); 
prothrombin time (PT) expressed in seconds is optional ).
Patients taking coumarin -derivative anticoagulants should b e monitored closely  and their 
anticoagulant dose adjusted as needed . 
[IP_ADDRESS] Biochemistry
Biochemistry  includes alanine aminotransferase, aspartate aminotransferase, gamma -glutamy l 
transferase, alkaline phosphatase, amylase, lipase, 
total bilirubin, sodium, potassium, calcium, 
magnesium, blood urea nitrogen or urea, carbon dioxide/bicarbonate, chloride, creatinine, 
creatine phosphokinase, total protein, albumin, glucose, trigly cerides, total cholesterol, 
phosphorus, and lactate dehy drogenase. Biochemistry  will also include creatinine clearance 
(Cockcroft and Gault, 1976 )on Day  1 of each cy cle.
[IP_ADDRESS] Urinalysis
Urinaly sis include s
  pH, specific gravity , protein, glucose , bilirubin , nitrites and occult blood .
The urinal ysis may  be performed b y dipstick .
[IP_ADDRESS] Additional Renal Function Studies
Urine will be collected for testing of biomarkers suggestive of potential renal injury  (aquaporin -2, 
calbindin D28, and clusterin)
. Anal ysis of this additional urine sample will be performed at a 
central laboratory (instructions provided in laboratory  manual) .
6.3.5 Electrocardiograms
A 12 -
lead electrocardiogram is to be performed at the time points shown in Appendix 12.1.
Any abnormalities, including those that worsen from baseline, believed to be clinically  
significant in the medical and scientific judgment of the Investigator are to be recorded as AEs or 
SAEs.
During Part 1, measurement of the QT c interval may  be obtained according to the formula used 
by [CONTACT_8236], however , the Frideri cia formula is preferred
(Fridericia, 1920 ). During Part 2, 
the Fridericia formula should be used for all patients.
ADC The rapeutics ADCT -[ADDRESS_252186] -402-101 Protocol Amendment 7
Date of Protocol: [ADDRESS_252187]; 
however, an y unexplained lesion will be referred to a dermatologist for further evaluation and 
biopsy  if clinicall y warranted
. Any  clinicall y significant abnormalities, including those that 
worsen from baseline, are to be recorded as AEs or SAEs .
6.3.7 Vital Sign Measurements
Vital sign measurements will include arterial blood pressure, heart rate, respi[INVESTIGATOR_2842], and 
temperature. Any clinically  significant abnormalities, including those that worsen from baseline, 
are to be recorded as AEs or SAEs.
6.3.8 Weight
If possible, patients are advised to monitor their weigh t dail y starting cy le 1 day  1 and inform 
their investigator if their weight increase smore than 1 kg (2.2 
pounds ) from C ycle 1Day 1.
6.3.9 Eastern Cooperative Oncology Gr oup Performance S tatus
The patient’s performance status will be assessed according to the 
time points in the schedule of 
events (Appendix 12.1) using the ECOG performance status grades (Table 3; Oken , 1982 ).
Table 3.Definiti on of Eastern Cooperative Oncology Gr oup(ECOG) Performance S tatus 
Grades
Grade Definition
0 Fully active, able to carry on all predisease performance without restriction
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a 
light or sedentary nature, e.g., light house work, office work
2 Ambulatory and capable of all self -care but unable to carry out any work activities. 
Upand about more than 50% of waking hours
3 Capable of only limited self -care, confined to bed or chair more than 50% of waking 
hours
[ADDRESS_252188] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 56For the tissue sample provided at screening, blocks and slides should be packed in ice or cold 
packs prior to priorit y overnight shippi[INVESTIGATOR_007]. If available, a copy  of the original pathology  report 
containing the histopathological diagnosis should accompan y each specimen. Refer to the 
Laboratory  Manual for further information. 
Desired specimen characteristics are:
Tissues fixed in neutral buf fered forma lin (NBF);
Blocks preferable to slides;
If slides are supplied, sections must be:
oMounted on positively  charged slides of the correct type,
oTransferred to the slide in a water bath (not b y tape),
oNot have been baked,
oNot be paraf fin coated (the slide conta ining the mounted specimen should not have been 
dipped in paraf fin),
oStored at 4°C in an airtight container prior to shipment.
During the study , blood samples will be collected for PK, ADA, 
 
 and safet y anal yses(clinical chemistry  and hematology ).  
 
For PKandADA, blood samples 
are to be collected and processed on site according to the 
Laboratory Manual . The resulting serum samples should be aliquoted and stored frozen at 
≤ -70C unti l shipment. Each sample tube should be clearly  labeled with the following 
information: study  number, study  center number, patient number, tube identification, and the 
scheduled sampling time by  [CONTACT_4475] (and hour, when necessary ).
Serum and u
rine samples are to be packed in sufficient dry  ice and shipped from the study  center 
to the central laboratory . Once labeled , samples should be stored at ≤ -70°C until shipment . 
Samples should be shipped according to the sample shipment schedule provided in L aboratory  
Manual.  Samples may  be retained at the central laboratory  for up to [ADDRESS_252189] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 57Each sample tube should be clearly  labeled with the following information: Study  number, study  
center number, patient number, tube identification, and the scheduled sampling time b y day (and 
hour, when necessary ).
ADC The rapeutics ADCT -[ADDRESS_252190] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 587Statistical and Analytical Plan
Full details of the analy sis plan, including a more technical and detailed elaboration of the 
statistical analy ses will be provided in the statistical anal ysis plan (SAP).
7.[ADDRESS_252191] results.
7.2 Primary Endpoints
7.2.1 Primary Endpoints
Assessment of DL Ts (Section 6.3.1) and determination of the MTD (Section 3.2)
forADCT -402 during Part 1.
Determination of the recommended dose of ADCT -402 for Part 2 b y the DESC.
Assessment of safety  parameters for Part 1 and Part 2 (Section 6.3).
7.2.2 Secondary Endpoints
Determination of DOR, ORR, OS, and PFS ( Section 7.6.2 ).
Determination of PK parameters (Section 7.6.3) for ADCT - 402 (total antibody ; DAR ≥0), 
PBD -conjugated antibody  (DAR ≥1), and free warhead SG3199.
Measurement of ADAs to ADCT -[ADDRESS_252192] -402 
(Section 7.6.3 ).
 

ADC The rapeutics ADCT -[ADDRESS_252193] -402-101 Protocol Amendment 7
Date of Protocol: [ADDRESS_252194] to the intended differences between these 
cohorts, e.g. tumor subtypes, dosing regime n or dose levels, as well as the number of these 
cohorts, taking into account the limit on the overall number of patients as specified above and 
safet y/efficacy  data obs erved up to that decision point .
7.4 Analysis Sets
Fiveanaly sis sets will be used in this study :
The Safet yanalysis set willconsist of all patients who receive stud y drug
The DL T-evaluable anal ysis set will consist of all patients in Part 1 who receive study drug 
and exclud espatients who discontinue study  drug during Cycle 1 without experien cing a 
DLT.
The Ef ficacy  anal ysis set will consist of all patients with valid baseline data who receive who 
receive at least [ADDRESS_252195] dose of study  drug .
The PK 
analysissetwill consist of all patients who receive study  drug and have sufficient 
concentration data for PK anal ysis.
The Pharmacod ynamic analy sis set will consist of all patients who receive study  drug and 
have sufficient concentration data for analysis .
 
7.[ADDRESS_252196] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 607.6 Statistical Analysis Methodolo gy
7.6.1 Safety Analyses
[IP_ADDRESS] Analyses of Adverse Events
An AE will be considered to be a TEAE if it begins or worsens on or after first dose date and 
before last dose 
date + 84 days.Planned summaries of TEAEs are detailed in the statistical 
analysis plan and will i nclude:
All TEAEs .
All serious TEAEs .
All treatment -related TEAEs .
All treatment -related serious TEAEs .
All TEAEs resulting in study  drug discontinuation.
All DL Ts.
Other AE anal yses of interest will be specified in the SAP . 
The incidence of deaths and the primary  cause of death will be summarized.
[IP_ADDRESS] Clinical Laboratory Results
Clinical hematology , coagulation panel, biochemistry , and urinal ysis data will be summarized at 
each scheduled assessment. Numeric hematology  and biochemistry  results will be summariz ed 
using change from baseline. All results will be summarized using shift from baseline. Shifts for 
clinical laboratory  results that can be graded according to CTCAE version 4 .0
will be 
summarized by  [CONTACT_3229]. Shifts for other numeric laboratory  results will be by  
[CONTACT_5019]/normal/low flag. Shifts for all other laboratory  result s will be by  [CONTACT_13541]/abnormal flag.
Summaries by  [CONTACT_33029], and all data will be reported 
according to the nominal visit date for which it was r ecorded. Unscheduled data will be included 
in “worst case post baseline” summaries ,which will capture a worst case across all scheduled 
and unscheduled visits after the first dose of stud y treatment. Further details will be provided in 
the SAP.
[IP_ADDRESS] Additional Safety Assessments
The results of scheduled assessments of vital signs, physical examinations, ECOG performance 
status, and 12 -lead ECG s will be summarized. All data will be reported according to the nominal 
visit date for which it was recorded (i .e., no visit windows will be applied). Unscheduled data 
will be included in “worst case” summaries ,
which will capture a worst case across all scheduled 
and unscheduled visits after the first dose of stud y treatment. All data will be listed. Further 
details will be provided in the SAP.
ADC The rapeutics ADCT -[ADDRESS_252197] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 617.6.2 Efficacy Analysis
[IP_ADDRESS] Overall Response Rate
Overall response rate will be defined as the proportion of patients with a best overall response of 
CR orPR at the time each patient discontinues ADCT -
402. Percentage of ORR with its 95% 
confidence interval (CI) will be presented.
[IP_ADDRESS] Duration of Response
Duration of response will be defined among responders (CR or PR) as the time from the earliest 
date of first response until the first date of either disease progression or death due to an y cause.
The date of disease progression will be defined as the earliest date of disease progression as 
assessed b y the Investigator using the 2014 Lugano Classification for response ( Appendix 12.2).
For pat ients who have not progresse d or died at the time of the anal ysis, censoring will be 
performed using the date of the last valid disease assessment. I n addition, patients with disease 
progression or death after an extended loss to follow
-up will be censored at the date of the last 
validdisease assessment prior to the extended loss to follow - up. The data will be analy zed by  
[CONTACT_5263] -Meier method. The median duration of response and 95% CI will be presented. Further 
details will be outlined in the SAP.
[IP_ADDRESS] Overall Survival
Overall survival wi ll be defined as the time from the beginning of study  drug treatment until 
death due to an y cause. For patients who have not died at the time of the analy sis, censoring will 
be performed using the date the patient was last known to be alive. The data will be anal yzed by 
[CONTACT_5263] -Meier method. The median survival time and 95% CI will be presented. Further details 
will be outlined in the SAP.
[IP_ADDRESS] Progression -Free Survival
Progression- free survival will be defined among the efficacy  population ( Section 7.4 )as the time 
from first dose of stud y drug until the first date of either disease progression or death due to an y 
cause. The date of disease progression will be defined as the earliest date of radiological disease 
progression as assesse d by [CONTACT_210923] 2014 Lugano Classification for response 
(Appendix 12.2). For patients whose disease has not progressed or who have not died at the time 
of the anal ysis, censoring will be performe d using the date of the last valid disease assessment. In 
addition, patients with disease progression or who have died after an extended loss to follow -
up 
by [CONTACT_210924]-up. The data will be anal yzed by  [CONTACT_5263]- Meier method. The median PFS
time and 95% CI  will be presented. Further details will be outlined in the SAP.
7.6.[ADDRESS_252198] -402-101 Protocol Amendment 7
Date of Protocol: [ADDRESS_252199] dose of study  drug –date of first dose of 
study  drug + 1.
7.[ADDRESS_252200] and the clinical research associate will review 
them with site personnel.
The clinical research associate will review eCRFs for accuracy  and completeness by [CONTACT_210925], during on- sitemonitoring visits, and after transmission to the Sponsor ; any  
discrepancies will be resolved with the Investigator or designee, as appropriate. After entry  of the 
data into the clinical study database they  will be verified for accuracy .
7.7.[ADDRESS_252201] . The anal ysis data sets 
will be a combination of these data and data from other sources ( e.g., laboratory  data).

ADC The rapeutics ADCT -[ADDRESS_252202] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 63Clinical data management will be performed in acco rdance with applicable CRO standards and 
data cleaning procedures to ensure the integrit y of the data ( e.g., removing errors and 
inconsiste ncies in the data ). Adverse events will be coded using the Medical Dictionary  for 
Regulatory  Activities Version 16.0. C oncomitant medication s
will be coded using WHO Drug
Dictionary 01June 2013.
After database lock, each study  site will receive informatio nabout 
all of their site -specific eCRF 
data as entered into electronic data capture s ystemfor the study, including full discrepancy and 
audit history . Additionally , a copy  of all of the study site’s data from the study  will be created 
and sent to the Sponsor for storage. The CRO will maintain a duplicate copy  for its records. In all 
cases, patient initials will not be collected or transmitted to the Sponsor .
ADC The rapeutics ADCT -[ADDRESS_252203] -402-101 Protocol Amendment 7
Date of Protocol: [ADDRESS_252204]
Federal regulations and the Inte rnational Council for Harmoni sation (ICH) guidelines require 
that approval be obtained from an institutional review board ( IRB)
/independent ethics committee 
(IEC)before participation of human patients in research studies. Before study  onset, the protocol,
informed consent, advertisements to be used for the recruitment of study  patients, and an y other 
written information regarding this study  to be provided to the 
patient or the patient ’s legal 
guardian must be approved by  [CONTACT_1201]/IEC. Documentation of all I RB/IEC approvals and of the 
IRB/IEC compliance with the current version of ICH harmoni sedtripartite guideline E6: Good 
Clinical Practice (GCP) will be maintained by  [CONTACT_210926].
All IRB/IEC appr ovals should be signed b y the IRB/IEC chairman or designee and must identify  
the IRB/IEC name [CONTACT_3816], the clinical protocol by  [CONTACT_11777], and the 
date approval or a favorable opi[INVESTIGATOR_11744].
The Investigator is responsible for obtaining continued review of the clinical research at intervals 
not exceeding 1 year or otherwise specified by  [CONTACT_1201]/IEC. The Investigator must supply  the 
Sponsor or its designee with written documentation of continued review of the clinical researc h.
8.[ADDRESS_252205] their origin in the 
Declaration of Helsinki, ICH GCP , and all applicable regulations.
8.3 Patient Information and Consent
A written informed consent in compliance with IRB/IEC and local regulations shall be obtained 
from each patient before entering the study  or performing an y unusual or non-routine procedure 
that involves risk to the patient . An informed consent template may  be provided by  [CONTACT_210927]. If any  institution -specific modifications to study -related procedures are 
proposed or made b y the site, the consent should be reviewed b y the Sponsor or its designee or 
both before IRB/IEC submission. Once reviewed, the consent will be submitted by  [CONTACT_210928]/IEC for review and approval before the start of the study . If the 
ICF is revised during the course of the stud y, all patients on-study  must sign the revised form , 
unless otherwise indicated by  [CONTACT_1201]/I EC (local or global, as applicable). In such case, the 
reason for not re -consenting the patient should be documented .
Before recruitment and enrollment, each prospective patient or his or her legal guardian will be 
given a full explanation of the study  and be allowed to read the approved ICF. Once the 
Investigator is assured that the 
patient /legal guardian understands the implications of 
participating in the stud y, the patient /legal guardian will be asked to give consent to participate in 
the study  

ADC The rapeutics ADCT -[ADDRESS_252206] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 659Investigator’ s Obligations
The following administrative items are meant to guide the Investigator in the conduct of the 
study  but may  be subject to change based on industry  and government standard operating 
procedures ,
working practice documents, or guidelines. Changes will be reported to the I RB/IEC 
but will not result in protocol amendments.
9.1 Confidentiality
All laboratory  specimens, evaluation forms, reports, and other records will be identified in a 
manner designed to maintain patient confidentiality. All records will be kept in a secure storage 
area with limited access. Clinical information will not be released without the written per mission 
of the 
patient (or the patient’s legal guardian), except as necessary  for monitoring and auditing 
by [CONTACT_1034] , its designee, the FDA, or the IRB/I EC.
The Investigator and all employ ees and coworkers involved with this study  may  not disclose or 
use for an y purpose other than performance of the study  any data, record, or other unpublished, 
confidential information disclosed to those individuals for the purpose of the study . Prior written 
agreement from the Sponsor or its designee must be obtained f
or the disclosure of an y said 
confidential information to other parties.
9.[ADDRESS_252207] provide to the Sponsor a commitment 
to promptly  update this information if any  relevant changes occur during the course of the 
investigation and for 1 year following the completion of the study .
Neither the 
Sponsor nor the CRO is financially  responsible for further testing or treatment of any  
medical condition that may  be detected during the screening process. In addition, in the absence 
of specific arran gements, neither the Sponsor nor the CRO is financially  responsible for further 
treatment of the patient’ s disease.
9.3 Adverse Events and S tudy Report Requirements
By [CONTACT_210929]. In addition, the Investigator 
agrees to submit annual reports to the study  site IRB/IEC as appropriate.
The Sponsor will ensure that all relevant safet y information (SAEs and S[LOCATION_003]RSs) is repo rted to 
the FDA  and competent authorities of EU Me mber States, and to the IEC, in accordance with 
current legislation (US 21CFR.316 and EU Directive 2001/20/EC).
ADC The rapeutics ADCT -[ADDRESS_252208] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 669.4 Investigator Documentation
Prior to beginning the study , the Investigator will be asked to com ply with the current version of
ICH E6 8.2 , Title 21 of the CFR, and local regulations by [CONTACT_210930], including but not limited to:
IRB/IEC approval .
Original Investigator -signed Investigator agreement page of the protocol .
Form FDA  1572, fully  executed, and all updates on a new full y executed Form FDA 1572.
Curriculum vitae for the Investigator and each sub -Investigator listed on Form FDA 1572.
Financial disclosure information to allow the Sponsor to submit complete and accurate 
certification or disclosure statements required under [ADDRESS_252209] provide to the Sponsor a commitment to promptly  update this information if any  
relevant changes occur during the course of the investigation and for 1 year after the 
completion of the study .
IRB/IEC -
approved informed consent, samples of site advertisements for recruitment for this 
study , and any  other written information regarding this study  that is to be provided to the 
patient or legal guardian .
9.[ADDRESS_252210] the study  as outlined in this protocol in accordance wit h the 
current version of ICH E6 and all applicable guidelines and regulations.
9.7 Investigator’ s Final Report
Upon completion of the study , where applicable, the Investigator shou
ld provide the I RB/IEC 
with a summary  of the study  outcome and the Sponsor and r egulatory  authority (ies) with any  
reports required.
ADC The rapeutics ADCT -[ADDRESS_252211] -402-101 Protocol Amendment 7
Date of Protocol: [ADDRESS_252212]. These documents should be retained for a 
longer period, however, if required b y the applicable regulato ry requirements or by  [CONTACT_210931] . It is the responsibility  of the Sponsor to inform the Investigator /institution as to 
when these documents no longer need to be retained.
 
 
 

ADC The rapeutics ADCT -[ADDRESS_252213] -402-101 Protocol Amendment 7
Date of Protocol: [ADDRESS_252214] operating procedures.
10.1.2 Inspection of Records
Investigators and institutions involved in the study will permit study -
related monitoring, audits, 
IRB/IEC review, and regulatory  inspections by  [CONTACT_210932]. In the 
event of an audit, the Investigator agrees to allow the Sponsor , representatives of the Sponsor , or 
a regulatory  agency  access to all study  records.
The Investigator should promptly  notify  the 
Sponsor and the CRO of an y audits scheduled by  
[CONTACT_210933][INVESTIGATOR_210906] .
10.2 Management of Pr otocol Amendments and Deviations
10.2.1 Modification of the Protocol
Any change in the study  plan requires a protocol amendment . An Investigator may not make any  
changes to the stud y without I RB/IEC and Sponsor approval ,except those necessary  to remove 
an apparent immediate hazard to the patient . A protocol cha nge intended to eliminate an apparent 
immediate hazard to patient(s) may  be implemented immediately , but the circumstances of the 
change must be documented and 
submitted to the IRB/IEC and to the Sponsor for further 
evaluation . If the protocol is in need o f substantial 
changes, t he Sponsor will amend the p rotocol 
and seek approval from the appropriate regulatory authority (ies) before implementation . All 
amendments to the protocol must be reviewed and approved following the same process as the 
original prot ocol before the amended protocol can be implemented .
ADC The rapeutics ADCT -[ADDRESS_252215] -402-101 Protocol Amendment 7
Date of Protocol: [ADDRESS_252216] be notifie d 
as soon as possible. The Investigator will inform the governing IRB/IEC of all protocol changes 
issued by  [CONTACT_1034] i n accordance with the IRB/IEC’s established procedure.
10.3 Study Termination
The Sponsor has every  intention of completing the study ; howev er, the 
Sponsor reserves the 
right to discontinue the study  at any  time for clinical or administrative reasons.
The end of the stud y is defined as the date on which the last patient completes the last visit to the 
study  site (includes any end of t reatment visit to the site and an y visit to the site to obtain 
confirmatory  scan of response ).
10.4 Final Report
Whether the study  is completed or prematurel y terminated, the Sponsor will ensure that the 
clinical study  reports are prepared and provided to regulatory  agency(ies) as required by  [CONTACT_210934](s). 
A
n Investigator will be identified to act as the signatory  forthe clinical study  report. 
TheInvestigator will be provided access to statistical tables, figures, and relevant reports and 
will have the opportunity to review the complete study  results.
ADC The rapeutics ADCT -[ADDRESS_252217] -402-101 Protocol Amendment 7
Date of Protocol: [ADDRESS_252218] P W , Hartley JA, Williams DG,and Chester KA  (2012). Antibody -drug 
conjugates -
a perfect s ynergy. Expert Opin Biol Ther 12(9):1 191-1206.
[COMPANY_010], Thousand Oaks, Ca lifornia [LOCATION_003]  (2014) . Prescribing information for b linatumomab 
(Blincy to), Accessed on 21 May  2015 at 
http://pi.amgen.com/united_states/blincy
to/blincyto_pi_hcp_english.pdf.
Anderson KC, Bates MP, Slaughenhoupt BL, Pi[INVESTIGATOR_66822], Schlossman SF, and Nadler LM (1984) . 
Expression of human B cell-associated antigens on leukemias and l ymphomas:  a model of 
human B cell dif ferentiation. Blood 63(June):1424 -
1433.
Ansell SM (2015). N on-hodgkin l ymphoma:  diagnosis and treatment. Mayo Clin Pr oc
90(8):1 152-1163.
Blanc V , Bousseau A, Caron A, Carrez C, LutzRJ, and Lambert JM (2011). SAR3419:  an anti
-
CD19- maytansinoid immunoconjugate for the treatment of B -cell malignancies. Clin Cancer Res 
17(20):6448-6458.
Cairo MS. Coif fier B, Reiter A, and Younes A, onbehalf of the TLS Expert Panel (2010) . 
Recommendations f or the evaluation of risk and prophy laxis of tumour ly sis sy ndrome (TL S) in 
adults and children with malignant diseases: an expe rt TLS panel consensus. Br J Haem
149:578–586.
Carter RH and Barrington RA (2004). Signaling by [CONTACT_8671]19/CD21 complex on B cells. Curr 
Dir Autoimmun 7:4–32.
Chao MP  (2013). T reatment challenges in the management of relapsed or refractory
 
non-Hodgkin’ s lymphoma – novel and emerging therapi[INVESTIGATOR_014] . Cancer Manag Res 5: 251 –269. 
Published online 2013 Aug 23. doi:10.2147/CMAR.S34273
Chen DR and Cohen PL(2012). Living life without B cells: is repeated B- cell depletion a safe 
and effective long -term treatment plan for rheumatoid arthritis? Int J Clin Rheumtol 7(2):159-
166.
Cheson BD, Fisher RI, Barrington SF,
Cavalli F , Schwartz H, and Lister T(2014).
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and Non -
Hodgkin l ymphoma: The L ugano classification . J Clin Onc 32(27):3059 -3068
Cockcroft DW andGault MH, (1976) .Prediction of creatinine clearance from serum creatinine. 
Nephr on16(1) :31- 41.
Cooper L J, Al-Kadhimi Z, DiGiusto D, Kalos M, Colcher D, Raubitschek A, et al (2004). 
Developme nt and application of CD19 -specific T cells for adoptive immunotherap y of B cell 
malignancies. Blood Cells Mol Dis 33(1):[ADDRESS_252219]  (2015) . Non -hodgkin 
lymphoma . Accessed 2 Aug 2015 on Cancer Netw ork at 
http://www .cancernetwork.com .
Fridericia L S. The duration of sy stole in the electrocardiogram of normal subjects and of patients 
with heart disease. Act Med Scand 1920, 53:469–486.  Translation published in 2003 in Annals 
Noninvasive Electrocardiology  8(4):[ADDRESS_252220] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 71Gerber HP, Kung -Sutherland M, Stone I, Morris -Tilden C, Miy amoto J, McCormick R
, et. al.
(2009). Potent antitumor activity  of the anti -CD19 auristatin antibody  drug conjugate hBU12-
vcMMAE agains t rituximab -sensitive and 
-resistant ly mphomas. Blood 113(18): 4352-4361.
Haas KM and Tedder TF (2005). Role of the CD19 and CD21/[ADDRESS_252221] defense and autoimmunity . Adv Exp Med Biol 560:125 –139.
Hartley  JA (201 1a). The de velopment of p yrrolobenzodiazepi[INVESTIGATOR_33005]. Expert 
Opin Investig Drugs 20(6): 733 -744.
Hartley  JM, Spanswick VJ, and Hartley  JA (2011b). Measurement of DNA  damage in individual 
cells using the single cell gel electrophoresis (comet) assay . Methods Mol Biol 731:309 -320.
Jabbour E, O’Brien S, Ravandi F, and Kantarjian H (2015). Monoclonal antibodies in acute 
lymphoblastic leukemia. Blood 125(26):4010- 4015.
Kimby  E (2005). Tolerability  and safety  of rituximab (MabThera). Cancer Treat Rev 31(6):45 6-
473.
Mounier N and Gisselbrecht C (2011)
. Stem cell transplantation for dif fuse large B -cell 
lymphoma patients in the rituximab era . Curr Opin Oncol 23(2):209 -213.
Muniz C, Martin- Martin L, Lopez A, Sanchez -Gonzalez B, Salar A, Almeida J, et. al. (2014).
Contribution of cerebrospi[INVESTIGATOR_210907]19 levels to the detection of CNS lymphoma and its 
impact on disease outcome. Blood 123(12): 1864 -1869.
National Cancer Institute (2015). SEER Stat Fact Sheets: Non -Hodgkin L ymphoma . Accessed at 
http://seer .cancer .gov/statfacts/html/nhl.html .
The Non -Hodgkin’ s Lymphoma Classification Project (1997) . A clinical evaluation of the 
international ly mphoma study  group classification of Non- Hodgkin’ s Lymphoma . Blood
89(11): 3909 -3918.
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE , McFadden ET, and Carbone PP (1982) . 
Toxicity  and response criteria of the Eastern Cooperative Oncology  Group. Am J Clin Oncol
5(6): 649 -55.
Roguska MA, Pedersen JT, Henry AH, Searle SM, Roja
CM, AveryB, et.al.(1996). A 
comparison of two murine monoclonal antibodies humanized by  [CONTACT_210935] -grafting and variable 
domain resurfacing. Protein Eng 9(10):895-904.
Rudin CM, Pi[INVESTIGATOR_33006], Bauer TM, Spi[INVESTIGATOR_43942], Read y N, Morgansztern D, et al.  Safet y and 
efficac y of single -agent rovolpi[INVESTIGATOR_33007] (SC16LD6.5), a delta -like protein 3 (DLL3)-
targeted antibody -drug conjugate (ADC) in recurrent or refractory  small cell lung cancer (SCL C).  
J Clin Oncol 34 (2016) (suppl: abstr LBA8505).
Scheuermann RH a nd Ra cilaE (1995). CD19 antigen in leukemia and l ymphoma diagnosis and 
immunotherapy . Leuk L ymphoma 18(5-6):385 -397.
Smith TJ (Chair), Khatcheressian J, LymanGH, Ozer H, Armitage JO, Balducci L, et.al.(2006). 
2006 Update of recommendations for the use of white blood cell growth factors: an evidence -
based clinical practice guideline. J Clin Onc 24(19):3187 -3286.
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pi[INVESTIGATOR_27604], Stein H, et.al.editors (2008) . 
WHOClassification of Tumors of Hematopoietic and L ymphoi d Tissues, 4thed., L ynon, [LOCATION_009].
ADC The rapeutics ADCT -[ADDRESS_252222] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 72Tedder TF (2009). CD19: a promising B cell target for rheumatoid arthritis (2009) . Nat Rev 
Rheumatol 5:572–577; doi:10.1038/nrrheum.2009.184.
Wang K, W eiG, and Liu D (2012). CD19: a biomarker for B cell development, ly mphoma 
diagnosis and therap y. Exp Hematol Oncol 1(1):36.
Wu J, Clingen PH, Spanswick VJ, Melinas
-Gomez M, Mey erT, Puzanov I, et.al.(2012). 
g-H2AX foci formation as a pharmacod ynamic marker of DNA  damage produced by  [CONTACT_210936] -linking agents: results from 2 phase I clinical trials of SJG -136 (SG2000). Clinl Can Res, 
published online December 18, 2012; DOI: 10.1 158/[ADDRESS_252223] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 7312Appendices
12.1
Appendix: Schedule of Events 
Timings for study  procedures are shown in Section 12.1.[ADDRESS_252224] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 7412.1.1 Schedule of S tudy Procedures
Proce
dureScreen Cycle 1 Cycle 2
Day –28
to –1Day 
1Day 
21Days 
3 and 52Day 8
(±2 days)Day 15
(±2 days)Day 2 83(±
2 days)Day 1
(±3 days)Day 
21Days 
3and 52Day 8
(±2 days)Day 15
(±2 days)Day [ZIP_CODE]
(±2 days)
Informed consent X
Dem ography X
Medical histor y4X
Blood or urine β -HCG X X5
Physical examination [ADDRESS_252225] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 75Pro
cedureCycles 3 until Progression/ Discontinuation
EOT
Within 30 days 25F2512-Week Follow -up Visit 26F26Long
-term  
Follow -up 27FDay 1
(±3 days )Day 827
(±2 days)Day 283
(±3 days)
Informed consent
Dem ography
Medical history4
Blood or urine β -HCG5X X
Physical examination6X X
Vital signs7X8X X X
Height
Weight X X X X
ECOG performance status X X X
Tumor tissue collection
Disease assessment X [ADDRESS_252226] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 76Abbreviations:   ADA, anti -drug antibody; ;ECG, electrocardiogram; EOI, end of ADCT -402 infusion; EOT, end of treatment; 
ECOG, Eastern Cooperative Oncology Group; HCG, human chorionic gonadotropin; PK, pharmacokineti cs; 
1 Day 2to occur 24 hours (±10%) after EOI.
2 Day 3 to occur 48 (±10%) hours after EOI.  Day 5 to occur 96 hours (±1 day) after EOI.
[ADDRESS_252227] transitioned to a reduced dosing frequency based on response (see Section 3.1 ) this visit will be required for Safety/PK 
Monitori ng.  For patients in Part 1, this visit will be done approximately [ADDRESS_252228] Day 1 (every 6 weeks) and at EOT.   
[ADDRESS_252229] -402.
7 Vital signs to include arterial blood pressure, heart rate, respi[INVESTIGATOR_697], and body temperature . Vital signs window  is 
±15 minutes.
8 Vital signs :On Day [ADDRESS_252230] -402 infusion, every 30 minutes during the infusion, 
at the end of infusion, and at 1, 3, and 6 hours after the end of infusion.  If no clinically significant changes occur durin g Cycles 1 and 2, vital sign
measurements are to be obtained prior to infusion start and end of infusion for all subsequent infusions. If clinically signi ficant changes in vital signs are 
observed at Cycle 1 and/or [ADDRESS_252231] -402 infusion for all subsequent cycles.
 
 
10 Modification to a patient’s treatment schedule w ill be based on an independent revie w of images unless otherwise approved by [CONTACT_456]. Therefore, 
the decision to delay treatment and/or reduce dose based on response will require independent verification of the local respo nse assessment (see
Section 6.1).Refer to Sections 4.1.[ADDRESS_252232] reduced dosing frequency.
11 Assessment of Dis ease at Screening
Positron emission tomography -computed tomography (PET CT) and diagnostic CT of the neck/chest/abdomen/pelvis and other areas of known 
disease or newly suspected disease with a clinical examination for lymphoma. Contrast should be used unless contraindicated. Magnetic resonance 
imaging (MRI) is permitted if diagnostic CT is contraindicated. The same assessments methods used at Screening which identify sites of disease 
should be used uniformly for all subsequent assessments. If PET -CT is positive, subsequent diagnostic CT and MRI are not needed unless clinically 
indicated
PET-CT only required at Screening for 18F -fluorodeoxyglucose (FDG) avid, nodal lymphomas (defined as per the Lugano Classification criteria as 
essentially all eligible hi stologies except small lymphocytic lymphoma, lymphoplasmacytic lymphoma/WM, mycosis fungoides, and marginal zone 
NHLs, unless there is a suspi[INVESTIGATOR_210900]). If PET -CT examination is negative at Screening, subsequent PET -CT is not 
requi red.
12  Hem atology: CBC to include WBC w ith 3-or 5-part differential, platelet count, hemoglobin, hematocrit, and ANC . 
13 Sam ples for hematology, coagulation panel, biochemistry, urinalysis, and additional renal function studies will be collected:
<[ADDRESS_252233] 402 infusion on Day 1 of Cycle 1, or
<[ADDRESS_252234] -402-101 Protocol Amendment 7
Date of Protocol: [ADDRESS_252235] include partial thromboplastin time (PTT) and International Normali zed Ratio (INR );  prothrombin time (PT) is optional.
15 Biochemistry includes alanine aminotransferase, aspartate aminotransferase, gamma -glutamyl transferase, alkaline phosphatase, amylase, lipase, total 
bilirubin, sodium, potassium, calcium, magnesium, b lood urea nitrogen or urea, carbon dioxide/bicarbonate, chloride, creatinine, creatine phosphokinase, 
total protein, albumin, glucose, tr iglycerides, total cholesterol, phosphorus, and lactate dehydrogenase . At Day 1 of each cycle, biochemistry will includ e 
creatinine clearance (calculated using the Cockcroft and Gault formula [Cockcroft and Gault, 1976 ]).
16 Urinalysis to include
, pH, specific gravity, protein, glucose , ketones, nitrates, occult blood and bilirubin . The urinalysis can be done by [CONTACT_5230].
17 Urine to be collected for testing of biomarkers suggestive of potential renal injury (aquaporin -2, calbindin D28, and clusterin).
[ADDRESS_252236] 40 2 infusion, within
30minutes of the end of infusion, and 3 (± 30 minutes) and 24 (± 2.4) hours after the end of infusion.
[ADDRESS_252237] -402:  Patients wi ll receive a 1 -hour IV infusion at escalating doses, on Day 1 of each 3 -week (21 -day) cycle. If ADCT -[ADDRESS_252238] cycle, the infusion duration may be shortened to 30 minutes for s ubsequent cycles for that patient, at the Investigator’s discretion . Variations in 
infusion times due to minor differences in IV bag overfill/under fill and the institution’s procedure for flushing chemothera py lines will not result in 
protocol deviation.
[ADDRESS_252239] -402and prior to the initiation of new anticancer treatment .When EOT coincides with 
a scheduled visit, the scheduled v isit will become EOT.
26 Follow -upto occur 12 (±1) we eks after last dose of ADCT -402.
27 After completion of 6 treatment cycles (e.g., 6 infusions), the Day 8 visit is not required unless clinically indicated.
28 PK sample collection on Day 8 Cycles 1 -
4.  Refer to Section 6.1, Efficacy Assessments . 
29 Sam plefor assessment of PK and ADA to be obtained 12 weeks (± 1 w eek) after last dose of ADCT -402, unless a new anticancer treatment has been 
initiated.

ADC Therapeutics ADCT-[ADDRESS_252240]-402-101 Protocol Amendment 7 
Date of Protocol: [ADDRESS_252241] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 7912.2
Appendix: Response Assessment of Hodgkin and Non-
Hodgk in Lymphoma (Lugano Classification) 
Response Assessment of Hodgkin and Non -Hodgkin L ymphoma (Lugano Classification)
Response / Site PET -CT-Based Response CT-Based Response
Complete Complete metabolic response Complete radiologic response
(all of the following)
Lymph nodes and 
extralymphatic sitesScore 1, 2, or 3* with or without a residual 
mass on 5PS**
Note: Uptake may be greater than normal 
mediastinum and/or liver in Waldeyer’s ring 
or extranodal sites with high physiologic 
uptake o r with activation within spleen or 
marrow ( e.g., with chemotherapy or myeloid 
colony -stimulating factors). In this 
circumstance, complete metabolic response 
may be inferred if uptake at sites of initial 
involvement is no greater than surrounding 
normal tissue even if the tissue has high 
physiologic uptakeTarget nodes/nodal masses must regress to
≤1.5 cm in LD
No extralymphatic sites of disease
Nonmeasured lesion Not applicable Absent
Organ enlargement Not applicable Regress to normal
New lesions None None
Bone marrow No evidence of FDG -avid disease in marrow Normal by [CONTACT_5293]; if indeterminate, IHC 
negative
Partial Partial metabolic response Partial rem ission
(all of the following)
Lymph nodes and 
extralymphatic sitesScore 4 or 5** with reduced u ptake compared 
with baseline and residual mass(es) of any 
size.
At interim, these findings suggest responding 
disease.
At end of treatment, these findings indicate 
residual disease.≥50% decrease in SPD of up to 6 target 
measurable nodes and extranodal sites
When a lesion is too small to measure on CT, 
assign 5 mm × 5mm as the default value.
When no longer visible, 0 × 0 mm
For a node >5 mm × 5 mm, but smaller than 
normal, use actual measurement for 
calculation
Nonmeasured lesion Not applicable Absent/normal, regressed, but no increase
Organ enlargement Not applicable Spleen must have regressed by >50% in 
length beyond normal
New lesions None None
ADC Therapeutics ADCT -[ADDRESS_252242] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 80Response Assessment of Hodgkin and Non -Hodgkin L ymphoma (Lugano Classification)
Response / Site PET -CT-Based Response CT-Based Response
Bone marrow Residual uptake higher than uptake in normal 
marrow but reduced compared with baseline 
(diffuse uptake compatible with reactive 
changes from chemotherapy allowed). If there 
are persistent focal changes in the marrow in 
the context of a nodal response, consideration 
should be given to further evaluation with 
MRI or biopsy or an interval scanNotapplicable
No response or stable 
diseaseNo metabolic response Stable disease
Target nodes/nodal 
masses, extranodal 
lesionsScore 4 or 5 with no significant change in 
FDG update from b aseline at interim or end of 
treatment<50% decrease from baseline in SPD of up to 
6 dominant, measurable nodes and extranodal 
sites; no criteria for progressive disease are 
met
Nonmeasured lesions Not applicable No increase consistent with progression
Organ enlargement Not applicable No increase consistent with progression
New lesions None None
Bone marrow No change from baseline Not applicable
Progressive disease Progressive metabolic disease Progressive disease 
(requires at least 1 of the following )
Individual t arget 
nodes/nodal massesScore 4 or 5 with an increase in intensity of 
uptake from baseline and/or[COMPANY_003] progression
Extranodal lesions New FDG -avid foci consistent with 
lymphoma at interim or end oftreatment 
assessmentAn individual node/le sion must be abnormal 
with:
LDi > 1.5 cm and
Increase by ≥50% from [COMPANY_003] nadir and 
An increase in LDi or SDi from nadir
0.5 cm for lesions ≤ 2 cm
1.0 cm for lesions > 2 cm
In the setting of splenomegaly, the splenic 
length must increase by > 50% of the exte nt of 
its prior increase beyond baseline (e.g., a [ADDRESS_252243] increase to > 16 cm). If no 
prior splenomegaly, must increase by [CONTACT_2669] 
2 cm from baseline
New or recurrent splenomegaly
Nonmeasured lesions None New or clear progression of preexisting
nonmeasured lesions
ADC Therapeutics ADCT -[ADDRESS_252244] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 81Response Assessment of Hodgkin and Non -Hodgkin L ymphoma (Lugano Classification)
Response / Site PET -CT-Based Response CT-Based Response
New lesions New FDG -avid foci consistent with 
lymphoma rather than another etiology ( e.g., 
infection, inflammation). If uncertain 
regarding etiology of new lesions, biopsy or 
interval scan may be consideredRegrowth of previously reso lved lesions
A new node > 1.5 cm in any axis
A new extranodal site > 1.0 cm in any axis; if 
< 1.[ADDRESS_252245] be attributable to 
lymphoma
Assessable disease of any size unequivocally 
attributable to lymphoma
Bone marrow New or recurrent FDG -avid foci New or recurrent involvement
Abbreviations: 5PS, 5 -point scale; CT, computed tomography; FDG, fluorodeoxyglucose; IHC, immunohistochemistry; LDi, 
longest transverse diameter of a lesion; MRI, magnetic resonance im aging; PET, positron emission tomography; [COMPANY_003], cross 
product of the LDi and perpendicular diameter; SDi, shortest axis perpendicular to the LDi; SPD, sum of the product of the 
perpendicular diameters for multiple lesions.
* A score of [ADDRESS_252246] treatment, especially if at the time of an interim scan. 
However, in trials involving PET where de-escalation is investigated, it may be preferable to consider a score of 3 as inadequate 
response (to avoid undertreat ment). Measured dominant lesions: Up to six of the largest dominant nodes, nodal masses, and 
extranodal lesions selected to be clearly measurable in two diameters. Nodes should preferably be from disparate regions of t he 
body and should include, where appl icable, mediastinal and retroperitoneal areas. Non -nodal lesions include those in solid organs 
(e.g., liver, spleen, kidneys, lungs), GI involvement, cutaneous lesions, or those noted on palpation. Nonmeasured lesions: Any 
disease not selected as measured, dominant disease and truly assessable disease should be considered not measured. These sites 
include any nodes, nodal masses, and extranodal sites not selected as dominant or measurable or that do not meet the 
requirements for measurability but are still considered abnormal, as well as truly assessable disease, which is any site of 
suspected disease that would be difficult to follow quantitatively with measurement, including pleural effusions, ascites, bo ne 
lesions, leptomeningeal disease, abdominal masses , and other lesions that cannot be confirmed and followed by [CONTACT_9661]. In 
Waldeyer’s ring or in extranodal sites ( e.g., GI tract, liver, bone marrow), FDG uptake may be greater than in the mediastinum 
with complete metabolic response, but should be no highe r than surrounding normal physiologic uptake ( e.g., with marrow 
activation as a result of chemotherapy or myeloid growth factors).
** PET 5PS: 1, no uptake above background; 2, uptake ≤ mediastinum; 3, uptake > mediastinum but ≤ liver; 4, uptake 
moderately > liver; 5, uptake markedly higher than liver and/or new lesions; X, new areas of uptake unlikely to be related to
lymphoma.
Referenc e:  Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz H, ListerTA . Recommendations for initial evaluation, 
staging, and response assessment of Hodgkin and Non
-Hodgkin lymphoma:  The Lugano classification . J Clin Onc 2014, 
32(27):[ADDRESS_252247] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 8212.3
Appendix: CTCAE Immune System Hypersensitivity Grades
Adverse Event Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
Allergic reaction Transient 
flushing or rash, 
drug fever 
<38C
(<100.4 F); 
intervention not 
indicatedIntervention or 
infusion 
interruption 
indicated; respo nds 
prom ptly to 
symptomatic 
treatment ( e.g.,
antihistamines, 
NSAIDS, 
narcotics); 
prophylactic 
medications 
indicated for ≤24
hoursProlonged ( e.g.,
not rapi[INVESTIGATOR_140022]/or brief 
interruption of 
infusion); 
recurrence of 
sympto ms 
following initial 
improvement; 
hospi[INVESTIGATOR_210908] 
(e.g., renal 
impairm ent, 
pulmonary 
infiltrates)Life-threatening 
consequences;
urgent intervention 
indicatedDeath
Definition: A disorder characterized by [CONTACT_210937] o r general response from exposure to an allergen.
Anaphylaxis - - Symptomatic 
bronchospasm, 
with or without 
urticaria; parenteral 
intervention 
indicated; 
allergy -related 
edema/angioedema
; hypotensionLife-threatening 
consequences;
urgent 
intervention 
indic atedDeath
Definition: A disorder characterized by [CONTACT_210938] -like substances from mast cells, causing a hypersensitivity immune response. Clinically, it 
presents with breathing dif ficulty, dizziness, hypotension, cyanosis ,and loss of consciousness and may lead to 
death.
ADC Therapeutics ADCT -[ADDRESS_252248] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 83Adverse Event Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
Autoimmune 
disorderAsymptomatic; 
serologic or 
other evidence 
of autoimmune 
reaction, w ith 
norm al organ 
function;
intervention not 
indicatedEvidence of 
autoimmune
reaction involving 
a non -essential 
organ or function 
(e.g.,
hypothyroidism)Autoimmune 
reactions involving 
major organ ( e.g.,
colitis, anemia, 
myocarditis, 
kidney)Life-threatening 
consequences;
urgent intervention 
indicatedDeath
Definition: A disorder resulting from loss of function or tissue destruction of an organ or multiple organs, 
arising from humoral or cellular immune responses of the individual to his own tissue constituents.
Cytokine release 
syndromeMild 
reaction; 
infusion 
interruption 
not 
indicated; 
intervention 
not 
indicatedTherapy or 
infusion 
interruption 
indicated but 
responds promptly 
to symptomatic 
treatment ( e.g.,
antihistamines, 
NSAIDS, 
narcotics, 
intravenous fluids); 
prophylactic 
medications 
indicated for 
≤24hoursProlonged ( e.g.,
not rapi[INVESTIGATOR_140022]/or brief 
interruption of 
infusion); 
recurrence of 
symptoms 
following initial 
improvement; 
hospi[INVESTIGATOR_210908] 
(e.g., renal 
impairm ent, 
pulmonary 
infiltrates)Life-threatening 
consequences; 
pressor or 
ventilatory 
support indicatedDeath
Definition: A disorder characterized by [CONTACT_33234], headache, tachycardia, hypotension, rash, and shortness of 
breath; it is caused by [CONTACT_210939].
ADC Therapeutics ADCT -[ADDRESS_252249] -402-101 Protocol Amendment 7
Date of Protocol: 16 October 2017 Page 84Adverse Event Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
Serum s ickness Asymptomatic; 
clinical or 
diagnostic 
observations 
only; 
intervention 
not indicatedModerate 
arthralgia; fever, 
rash, urticaria, 
antihistamines 
indicatedSevere 
arthralgia or 
arthritis; 
extensive 
rash; steroids 
or intravenous 
fluids 
indicatedLife-threatening 
consequences; 
pressor or 
ventilatory 
support indicatedDeath
Definition: A disorder characterized by a delayed -type hypersensitivity reaction to foreign proteins derived 
from an animal serum. It occurs approximately [ADDRESS_252250] marked 
discomfort, and dyspnea.
Immune 
system 
disorders -
Other, specifyAsymptomatic or 
mild symptoms; 
clinical or 
diagnostic 
observations 
only; 
intervention not 
indicatedModerate; 
minimal, local or 
noninvasive 
intervention 
indicated; 
limiting 
age-appropriate 
instrumental 
ADLSevere or 
medically 
significant but 
not immediately 
life-threatening; 
hospi[INVESTIGATOR_210909]; 
disabling;
limiting self -
care ADLLife-threatening 
consequences;
urgent 
intervention 
indicatedDeath
Abbreviations: ADL, Activities of daily living; NSAIDs, non -steroidal anti -inflammatory drugs.
Adapted f rom CTCAE 4.0 – June 14, 2010, Immune system disorders .